

# PASPCR

December 2002  
Vol. 10 Number 4

## Newsletter



### Introduction... by **Bill Oetting**

The *PASPCR Newsletter* is published quarterly and is intended to serve as a means of communication for the members of our Society. You are invited to contribute articles, or other information you feel will be of interest to members of the PASPCR. If you attend a scientific meeting and have heard results which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. Any information on upcoming meetings of interest will be added to the "Calendar of Events". We also want to note any change of affiliation or address that you may have had to help us keep our membership list up-to-date. This is your Newsletter, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to me, preferably by E-mail, to [bill@lenti.med.umn.edu](mailto:bill@lenti.med.umn.edu).

The PASPCR Web Site is the major, up-to-date source of current information for the PASPCR membership and for individuals who are interested in the PASPCR. The PASPCR Web site is not only includes new information, but it is also a repository on the history of our society, our goals and our by-laws. This site also includes a registration page for potential new members and I have received well over 30 requests over the last two years. This is a very cost effective means to disseminate information about the PASPCR. If there is additional information that you would like to see on the Web site, or you would like to include information of past PASPCR activities, please let me know and I will add them. A visit to our web site may be the first time that an individual has heard about the PASPCR, and we should present ourselves in the

best possible light. I look forward to your comments and inclusions.

The IFPCS web site can now be reached by using either domain name **ifpcs.org** or **ifpcs.info**. Updates are being made to the Mouse Coat Color Genes database at <http://www.cbc.umn.edu/ifpcs/micemut.htm>. If you know of any additions that should be included, please let me, or Dot Bennet, know and we will get that information included.

The Following Email was received by the PASPCR Newsletter office:

Hi Guys -

I just got my copy of the PASPCR Newsletter and was happy to see that the site of the PASPCR meeting next year has been moved from dreary and stodgy old Cape Cod to the fresh, polluted shores of Cape May, New Jersey.

OK, so I made a mistake. I printed the wrong URL to the Sea Crest Inn, where the XI<sup>th</sup> Annual PASPCR Meeting is being held. The correct URL is: [www.seacrest-resort.com](http://www.seacrest-resort.com). Check it out.

The PASPCR Web Site can be found at:

<http://www.paspcr.org>

### In this Issue . . . . .

PASPCR Officers.....	2
Calendar of Events.....	2
Corporate Sponsors.....	3
Message from the PASPCR President.....	3
Message from the IFPCS President.....	4
From the Editor.....	6
And now for the rest of the story.....	6
Members in the News.....	7
Notes from Cape Cod Bay.....	7
Mouse News.....	8
A Note from Lynn Lamoreux.....	8
Positions Wanted/Available.....	9
Bibliography.....	11

**The PanAmerican Society for  
Pigment Cell Research**

C/O Dr. Raymond E. Boissy  
Department of Dermatology  
University of Cincinnati  
231 Bethesda Avenue  
Cincinnati, OH 45267-0592

**Officers:**

Zalfa Abdel-Malek,  
*President*

John Pawelek  
*President-elect*

Raymond E. Boissy  
*Secretary/Treasurer*

**Council Members:**

Mary K. Cullen  
Bryan Fuller  
Ruth Halaban  
Thomas J. Hornyak  
Randy Morrison  
Brian Potterf  
Glynis Scott  
Miri Seiberg  
Vijay Setaluri

**IFPCS Representative:**

Richard A. King

**Calendar of Events:**

**June 21-24, 2003** First Melanoma Research Congress, to be held in Philadelphia, PA.

**Contact:** Dr. Meenhard Herlyn.

Email: Parsons@Wistar.upenn.edu

**Sept. 3-7, 2003** XI<sup>th</sup> Annual Meeting of the Pan-American Society for Pigment Cell Research, to be held in Cape Cod, MA.

**Contact:** Dr. Jean Bologna.

E-mail: jean\_bologna@qm.yale.edu.

**Sept. 17-20, 2003** XI<sup>th</sup> Annual Meeting of the European Society for Pigment Cell Research, to be held in Gent, Belgium.

**Contact:** Prof. JeanMarie Naeyaert.

E-mail: JeanMarie.Naeyaert@rug.ac.be.

**2004** XII<sup>th</sup> Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Irvine, California.

**Contact:** Frank Myskins.

E-mail: flmeyske@uci.edu

**2004** XII<sup>th</sup> Meeting of the European Society for Pigment Cell Research, to be held in Paris, France.

**Contact:** Dr. Lionel LaRue

E-mail: Lionel.Larue@curie.fr

**2005** XIV<sup>th</sup> International Pigment Cell Conference (IPCC), to be held in Bethesda, MD, USA.

**Contact:** Dr. Vince. Hearing

E-mail: hearingv@nih.gov

The *PASPCR Newsletter* is published quarterly by the PanAmerican Society for Pigment Cell Research. All views are those of the authors. For further information or to submit articles, please contact members of the Publications Committee.

**Publications Committee:**

**William S. Oetting, Ph.D.**  
**Editor**

University of Minnesota  
Department of Medicine- Genetics  
MMC 485  
420 Delaware St. SE  
(612) 624-1139  
bill@lenti.med.umn.edu

**Vijayasardhi Setaluri, Ph.D.**

Wake Forest University School of Medicine  
Department of Medicine  
Winston-Salem, NC 27157  
(336) 716-3273  
setaluri@bgsu.edu

**Giselle Thibaudeau, Ph.D.**

Mississippi State University  
Department of Biological Sciences  
Harned Hall  
Mississippi State, MS 39762  
(662) 325-7572  
giselle@ra.msstate.edu

## **Corporate Sponsors** *by Raymond E. Boissy*

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

### ***GOLD Corporate Patrons***

Procter and Gamble Co.  
Shiseido Co, Ltd.

### ***SILVER Corporate Patrons***

Avon Products, Inc.  
Galderma Laboratories, Inc  
Stiefel Laboratories  
Combe, Inc.

---

## **A Message from the President**

Dear PASPCR members,

It is the time to evaluate our society's achievements during the past year. Thanks to the efforts of enthusiastic Council members and the diligence of fellow Officers, we have been able to achieve the following:

- 1) Holding joint symposia with other scientific societies, namely the Society for Investigative Dermatology and American Society for Photobiology.
- 2) Co-organizing and participating in the XVIII International Federation for Pigment

Conference in Egmond aan Zee, in the Netherlands.

- 3) Putting in place active committees to improve the organization of our society. These committees are: Finance Committee, headed by Raymond Boissy, Nominations and Awards Committee, chaired by John Pawelek, Publication Committee, headed by Bill Oetting and Vijay Setaluri, Membership Committee, co-chaired by Raymond Boissy and Zalfa Abdel-Malek, and Annual Meeting Committee, chaired by Zalfa Abdel-Malek. I invite you to consider seriously participating in these committees in order to keep the vitality of PASPCR. If interested, please contact the appropriate chairperson.

An immediate goal for the society is to increase the membership of PASPCR. I challenge each one of you to recruit at least one new member. I urge principal investigators to encourage their graduate students and postdoctoral fellows to become members. As you know, PASPCR annual meetings have always been a friendly and supportive forum for young investigators. Our young scientists are the ones that will insure the continuity of the society and will be its future leaders.

We are very grateful for the generosity of the Skin Research Center of Johnson and Johnson for their support of the PASPCR sponsored Aaron B. Lerner Special Lectureship, for a period of five years, beginning in the year 2003. I also want to thank all our corporate sponsors for supporting the various activities of our society during the past year.

As I begin the second year of my term, I present to you these specific goals that I hope the society will achieve during this coming year:

- 1) Increasing PASPCR visibility and membership.

*Continued on next page*

2) Providing mentorship to young investigators, particularly by assisting them in grant writing and directing them to appropriate funding agencies. I urge our senior scientists to volunteer a little of their time to help our young investigators progress to become independent scientists.

As you know, our next annual meeting is in September, 2003, in Woodshole, MA. I look forward to seeing you there. I end my message by wishing you a joyful holiday season, and a happy new year.

**Zalfa Abdel-Malek, Ph.D.**  
PASPCR President

---



---

## **A message from the President of the International Federation of Pigment Cell Societies**

to members of the ESPCR, JSPCR and PASPCR  
<[www.ifpcs.org](http://www.ifpcs.org)>

Dear Friends and Colleagues,  
Seasonal Greetings, in a year when world events - although still regrettably far from universal peace - have at least seemed less terrible than in 2001. It is with great pleasure that I start to write the IFPCS President's message for the first time, although with a sense of disbelief. (Surely there must be some mistake? Could the real President please step forward?) More seriously, I will begin by expressing profound thanks to the outgoing Officers of the IFPCS: Shosuke Ito (President), Stan Pavel (Vice President) and Dick King (Secretary-Treasurer), with every appreciation of all their hard work for the Federation over the past three years. All members will surely join me in those thanks, and also in welcoming our other new IFPCS officers, Zalfa Abdel-Malek (Vice-President) and Yasushi Tomita (Secretary-Treasurer), and new IFPCS

Council members Lionel Larue and Ray Boissy.

It is genuinely a pleasure to have the chance to contribute to the running of the IFPCS. Our Federation of three Societies is relatively young, having been created in 1990 at the IPCC in Kobe, Japan. But it is a truly valuable and constructive organization. It has thrived from the outset, fostering its aims of scientific communication and co-operation within our expanding field of pigment-cell research. It has regularised the IPCC congresses, on a three-yearly basis. Many of us had the pleasure of attending the recent 18<sup>th</sup> IPCC in Egmond aan Zee, Netherlands. Congratulations once more to Stan Pavel, Nico Smit and their team for organizing on behalf of ESPCR such a first-rate selection of pigment-cell science, together with fine social events including a canal trip in Amsterdam and jam session back in Egmond. Those unable to attend can find the abstracts published as a supplement to *Pigment Cell Research*, and there are plans also to publish a selection of Proceedings in *Pigment Cell Research* during 2003.

We can expect another superb congress in the 19<sup>th</sup> IPCC, 2005, to be chaired by Vincent Hearing for PASPCR. Plans are impressively well developed already. It will be at the NIH, Bethesda, USA – a memorable visit in itself, and a short Metro ride from the sights of Washington. Before then, you can enjoy attending the annual meetings of your regional Pigment Cell Society – or maybe all three of them, occurring in 2003 in three delightful locations: Cape Cod (Massachusetts) and Ghent (Belgium), both in September, and Tokyo in November. From experience, you can expect excellent science, a constructive and friendly atmosphere and plenty of interaction. Please see the society web sites for information, or contact the organizers, respectively Drs John Pawelek <[john.pawelek@yale.edu](mailto:john.pawelek@yale.edu)>, Jean-Marie Naeyaert <[JeanMarie.Naeyaert@rug.ac.be](mailto:JeanMarie.Naeyaert@rug.ac.be)> and Genji Imokawa <[073733@kastanet.kao.co.jp](mailto:073733@kastanet.kao.co.jp)>.

Another familiar IFPCS activity is to support and promote the journal *Pigment Cell Research*, which under the outstanding editorship of Vincent Hearing (since 2000) has steadily increased its scientific quality, output and Impact Factor (now 2.1) – see also the Editorial in the December issue. You too can easily aid this progress. Just keep submitting good papers, cite recent *PCR* ar-

articles, and encourage your library and colleagues to subscribe to the journal. Much gratitude is due also for the continued and generous sponsorship of *PCR* by Johnson & Johnson, L'Oréal, Shiseido and Unilever. Lastly, congratulations to the new IFPCS Publications Committee, Drs Shibahara, Boissy and Larue, for recently persuading the publisher Blackwell to withdraw a proposed drastic increase in the price of *PCR*, from \$95 to \$137. Instead the price will increase more gradually, to only \$106 in 2003.

The IFPCS's aim of communicating information about our field is of course also well supported by the various Society web pages and Bulletins. The Federation is constantly indebted to our dedicated colleagues who capably provide these resources – Bill Oetting for both IFPCS and PASPCR; Ghanem Ghanem for ESPCR, and Kazu Wakamatsu and Shige Shibahara for JSPCR. Continuing thanks to all of them. Among these pages, please don't forget the IFPCS "InterPig" list of scientific resources for pigmentary research – <[www.ifpcs.org](http://www.ifpcs.org)>. If you have any such resources to offer that are not listed, now is a great time to send your information to Bill Oetting <[bill@lenti.med.umn.edu](mailto:bill@lenti.med.umn.edu)> or Hiro Yamamoto <[hyamamot@mail.cc.tohoku.ac.jp](mailto:hyamamot@mail.cc.tohoku.ac.jp)>.

Another useful activity has been the establishment of the IFPCS Special Interest Groups or SIGs – <[www.ifpcs.org](http://www.ifpcs.org)>. These groups aim for more-specific communication within sub-specialities of our field, and some of them have become impressively active. For example satellite meetings were organized at the 2002 IPCC by the SIGs for Melanoma, Pigment Cell Development and Hypo-/Hyperpigmentation. Indeed, the Melanoma Group, chaired by Meenhard Herlyn, has attracted massive interest and is set to transform into a full international society, the Melanoma Research Society, at its meeting in the USA next June. There seems to be a pressing need for such a society, and it is satisfying that the IFPCS could foster this development. More generally, research fields are in constant flux, and IFPCS Council is now reviewing the SIGs, and whether there are areas where new ones may be needed. I would welcome ideas on this from any of you – <[dbennett@sghms.ac.uk](mailto:dbennett@sghms.ac.uk)>. In fact, please contact me at any time, if you have any ideas for improv-

ing or adding to any aspect of IFPCS activities.

Another way you can contribute to your Society and Federation is to encourage others in the field to become members. The more researchers taking part in our networks, the more we can all learn and benefit from each other. The more subscriptions, the more invited speakers per conference, and the more travel grants for young scientists. So I urge those in each Society to do all you can to retain and add members, especially in any under-represented fields. You can be assured that your own membership is already promoting these valuable ends. There are many exciting developments in pigment cell research in the post-genomic era, and we should hope for record levels of participation.

Lastly, perhaps I should not ignore the remarkable situation that, after its first election of the new Millennium, the IFPCS has not only its first female President but also its first female Vice-President, while all three Society Presidents are also women. One good consequence is that our female members can now have more confidence that they are in no way excluded from the offices and honours of the Societies. On the other hand, I hope it will not be too long before male/female issues are no longer important, because the balance among scientists will have become equal. Meanwhile, anyone with concerns about such issues can still contact the IFPCS Women Scientists' Committee, the new members of which should be announced shortly in the IFPCS Web Pages.

In conclusion, may I wish all of you a very happy and peaceful year in 2003, with lots of fascinating new findings in pigment cell research.

Best wishes,  
**Dot Bennett** [President, IFPCS]

**Keep the membership informed.**

If you have news about a member of the PASPCR, please let us know. Contact a member of the publications committee and we will make sure that it is in the next issue.

**From the Editor –***by Vince Hearing*

Online journals and PDF files have generated a whole new layer of complexity for copyright issues dealing with journals and publishers. Officially, PDF files that you download (even of your own articles) are copyright restricted documents and you are not legally entitled to distribute them to others without permission of the publisher. Does anyone follow this guideline? Maybe not, but it is wise to be aware of it (does the Napster lawsuit ring a bell with anyone?).

In any case, Blackwell/Munksgaard, the publishers of *Pigment Cell Research*, have worked out a more streamlined copyright form that authors will be using as of this publication year (2003). It is a bit more complex than the earlier version, but it provides you some liberties previously not allowed, as listed below. If you are interested in seeing the new form, you can find it under the Instructions to Authors on the PCR web site ([www.pigment.org](http://www.pigment.org)).

Among other things, now you are allowed to:

- 1) post PDF files of your publications on your own web site, as long as you identify the source of the original citation (as an Editor's note, this would allow others to log on to your web site and download any PDF files you have at that site).
- 2) Use Figures you have published in subsequent publications without getting permission from the publishers, again if you identify the source of the original citation.

Do these guidelines apply to all scientific journals and publishers? Probably not, but hopefully they soon will. They certainly do apply to journals published by Blackwell/Munksgaard, which includes many of your favorite dermatology themed journals.

Other things to look forward to in *Pigment Cell Research* in 2003 –

- The line-up of scheduled Full Reviews, Pigment Gene Focus Reviews and Innovative Technology Reviews is almost set; they continue the high caliber of reviews you have seen in recent years and you can see those at the 'In Press' hyperlink on the PCR web site.
- The next 3 Bibliographic Reviews will be coming out in the next year or so; Prof. Masako Mizoguchi, Prof. Hans Rorsman and Prof. James J. Nordlund have agreed to write those and I am sure their insights about their research and clinical careers will make for very interesting reading.
- Did you miss the IPCC last September in The Netherlands? If so, or even if you were fortunate enough to attend, you'll be happy to know that a dozen or so selected lectures from that meeting will be highlighted in a special IPCC Proceedings section to be published as supplementary pages in Issue #3 of 2003.



As usual, I welcome all input and suggestions from scientists in the pigment cell community and please feel free to contact me at any time. Let me take this occasion to wish you, your colleagues and your family a happy, safe and prosperous 2003.

---



---

### **And now for the rest of the story.**

There is no story for this issue. Please look in the March issue for the next installment.

If you wish to know how a particular line of investigation got started, or know of a story that would be interesting to readers of the PASPCR Newsletter, please email me at [bill@lenti.med.umn.edu](mailto:bill@lenti.med.umn.edu), and I will try to get **the rest of the story**.

## Members in the News:

Ana Luisa Kadekaro, Ph.D., postdoctoral fellow in Zalfa Abdel-Malek's laboratory, Department of Dermatology, University of Cincinnati, was awarded a three-year Skin Research Grant by the Johnson and Johnson Skin Research Center, to fund the project entitled " $\alpha$ -Melanocortin and Endothelin-1 Promote Human Melanocyte Survival by Inhibiting Apoptosis in Response to Ultraviolet Radiation". Congratulations to Dr. Kadekaro.

## From Cape Cod Bay

by John Pawelek

The PASPCR XIth annual meeting, "Molecular and Genetic Characterization of Melanocytes and Melanoma Cells" will be held Sept. 4-7, 2003 at The Sea Crest Resort & Conference Center, North Falmouth, MA ([www.seacrest-resort.com](http://www.seacrest-resort.com)).

The subject categories for this meeting will be:

- Comparative models of pigmentation:
- Enzymology of melanogenesis
- Growth factors and signal transduction
- Hormones and receptors
- Melanocyte development
- Melanoma
- Molecular biology and gene action
- Pigmentary disorders
- Structure and function of melanin
- Subcellular organelle processing/trafficking.

We have an excellent list of invited speakers for overview lectures, including: Natalie G. Ahn, Greg Barsh, Borris Bastian, Marianne Berwick, Lynda Chin, Michael Detmar, David E. Fisher, John Hammer III, Daniel Hebert, Lynn Margulis, Maria S. Soengas, Walter Storkus, Robert Swank.

There are 14 young investigator travel awards (\$500) available. Abstracts are due May 1, 2003. The Sea

Crest Resort has its own beach on Cape Cod Bay, within easy driving distance of Woods Hole, and the Nantucket and Marth's Vineyard ferries. A New England lobster/clambake is on the fare. Come join us for a great meeting! Information for registration and abstract forms and travel awards are on the PASPCR web (<http://www.paspcr.org>).

For further information, please contact Dr. John Pawelek, Yale School of Medicine ([john.pawelek@yale.edu](mailto:john.pawelek@yale.edu); 203-785-4411).



From the Sea Crest Inn Web site:

This is Cape Cod as you've dreamed it would be. Pristine white sands lapped by a sparkling ocean, a private beach immaculately maintained. A resort with every amenity and opportunity to indulge in your favorite activity from tennis to swimming to dining. In a setting facing West, open to sea breezes and flooded with sunshine that deepens and glows into a fiery skyscape as the sun sinks below the horizon at night. Step into the special ambiance of Sea Crest life. ([www.seacrest-resort.com](http://www.seacrest-resort.com)).



## Mouse News

Some of our members participated in a recent meeting of the International Mammalian Genome Society, in San Antonio, Texas.

Members of this society are very active in the sequencing and mutagenesis and “phenotyping” of the mouse genome, which is ongoing primarily under the NIH Mouse Initiative in collaboration with similar efforts in Europe and Japan. You might be interested in checking out the resources listed on their web site at

<http://www.imgs.org/>

The goals of the society are quoted below from their web site:

“The International Mammalian Genome Society exists primarily to foster and stimulate research in mammalian genetics from sequencing and functional genomics to mutagenesis and mutant analysis. The activities of the society have expanded with the growing realization of the important and unique role of rodent species in current biomedical and genetic research.

The extensive mouse genetic resources and the identification of evolutionary conserved linkage relationships between mice and humans offer significant opportunities for understanding gene function in relation to human development and disease. The role of the mouse in current biomedical and genetic research will increase further as the benefits of comparative sequence analysis of the human and mouse genomes and large scale mutagenesis programs are obtained.”

*Lynn Lamoreux*

---

### Keep the membership informed.

If you have news about a member of the PASPCR, please let us know. Contact a member of the publications committee and we will make sure that it is in the next issue.

## A Note from Lynn Lamoreux

I believe strongly that a major advantage of the international and local pigment cell societies is that:

- A. We talk to each other, and especially,
- B. For the most part we accept and welcome people outside the mainstream. And of course also people in the mainstream, or we would all be in the backwater. But backwater or mainstream, both are needed for the promotion of creative science.

Since when did all good science arise in the mainstream? The mainstream is GREAT for implementing what we already know and for generating unanticipated spin-offs, both of which are good science. But if we more and more punish people outside the mainstream and deprive them of opportunity — to that extent we are losing the creative (i.e., different) inputs that would move the mainstream forward beyond what we already know (i.e., the cutting edge). The pigment cell societies are the group I know that most effectively fosters the kind of environment that allows both type of individuals to feel comfortable presenting their work. I had another person say the same to me at the last international meeting. He didn't use those words. Recently I heard two different people at vastly different stages of their careers, at a different sort of meeting, apologizing for their work because it was not just like all those reports that popped up onto the screen from all those from all those expensive laptop computers. In both cases, I found the deviant work more interesting.

*Lynn*





## Positions - Wanted and Available

Postings for **Positions Available** will be open to all individuals and institutions so long as the position is related to pigment cell research. Postings for **Positions Wanted** will be open only to members of the PanAmerican Society for Pigment Cell Research or its sister societies (JSPCR and ESPCR). Send postings to Bill Oetting at bill@lenti.med.umn.edu. Please provide an expiration date for any submitted postings. Final decisions will be made by the Publications Committee of the PASPCR.

### Postdoctoral Position

Polarized Kit-ligand expression in the epidermis: Its role in human melanocyte homeostasis

A postdoctoral position (fully funded for the first year with the possibility of a 2 year extension) is immediately available in the Department of Pathology, Centre Medical Universitaire at the University of Geneva, Switzerland. The project is supervised by Dr. Bernhard Wehrle-Haller and Prof. Beat Imhof and is within the frame of a collaboration between the University of Geneva and Industry.

The aim of this project is to understand the role of kit-ligand in melanocyte homeostasis in the adult epidermis and how manipulation of kit-ligand expression or localization in keratinocytes affect melanocyte behavior. The project will employ cell-biological, pharmaceutical, biochemical as well transgenic approaches (mouse) to develop methods to modify Kit-ligand localization (polarity and cell surface expression) in vivo and to study melanocyte behavior in response to such altered Kit-ligand presentation. For references and rationale see Wehrle-Haller and Imhof (2001, J. Biol. Chem. 276, 12667-74) and Grichnik et al., (1998, J. Invest. Dermatol. 111, 233-38).

The Centre Medical Universitaire provides a stimulatory research environment located within the City of Geneva. Research in the department is centered around problems of autoimmunity, wound healing, inflammation, cell-cell junctions and cell migration. Geneva, located at the lake of Geneva in close proximity to the French Alps, provides a rich multicultural environment facilitating social integration.

Interested candidates preferably having experience in one or more of the aforementioned domains should send their CV (e.g. e-mail) including names and contacting information of two references to:

Bernhard Wehrle-Haller PhD  
Department of Pathology  
Centre Medical Universitaire  
1. Rue Michel-Servet  
1211 Geneva 4  
Switzerland  
Tel/Fax: 0041 22 702 5735 / 5746  
Bernhard.Wehrle  
Haller@medecine.unige.ch

### Postdoctoral Research Position

A postdoctoral position is available immediately to study the transcriptional co-repressor and co-activator activities of the oncogenic protein Ski in human melanomas (PNAS (USA) 97:5924-5929, 2000). Seeking individuals with experience in EMSA, *in vitro* transcription-translation, site-directed mutagenesis and yeast two-hybrid screening. Interested individuals should send inquiries and applications (including CV, a brief description of past experience and future research interests, and the name of three references) to:

Estela E. Medrano, Ph.D.  
Huffington Center on Aging  
Baylor College of Medicine  
One Baylor Plaza N-803.01  
Houston, TX 77030

Baylor College of Medicine is an Equal Opportunity Employer

### Research Associate/Post Doctoral Fellow Position Available

Position available for either an entry level postdoctoral fellow or a more senior research associate to study the molecular and cellular biology of the melanocyte in general and the pathophysiology of vitiligo in specific. The research project will focus globally on the role of survival factors and apoptotic regulators on the viability of melanocytes in the skin and in culture. In addition, the project will focus on the genetic and cellular susceptibility of melanocytes from patients with vitiligo to under apoptosis in response to various stimuli. Postdoctoral fellow candidate should have experience with routine

molecular and cellular techniques including cell culturing, site directed mutagenesis, and protein biochemistry. Research Associate candidate should have similar experiences utilizing the melanocyte system. Candidate will become part of an interactive research group focusing of various aspects of pigmentation in the Department of Dermatology and on skin physiology in the Skin Sciences Institute within the University of Cincinnati College of Medicine. Send curriculum vitae and list of three references to:

Raymond E. Boissy, Ph.D.  
Professor of Dermatology and Cell Biology,  
Neurobiology, & Anatomy  
Department of Dermatology  
University of Cincinnati College of Medicine  
231 Albert Sabin Way, ML-0592  
Cincinnati, OH, 45267-0592  
TEL: 513-558-6242  
FAX: 513-558-0198  
E-mail: boissyre@email.uc.edu

### **Principal Scientist- Clinical Research - Skin Science Research**


Unilever employs over 200 scientists at our New Jersey Laboratory who are dedicated to innovative and scientifically rigorous skin research programs. Our world sales exceed \$40 billion so our programs have solid financial funding allowing for an innovative and challenging research culture. We currently have a full time opening that provides a unique opportunity to apply your basic science skills to human studies that impact the condition of skin for hundreds of millions people worldwide. We are seeking an expert in pigment biology or photobiology who can advance our knowledge and link laboratory research to clinically defined improvements of consumer skin problems. As a member of our skin research team, you will have an opportunity to work with other scientific experts in many fields including cell biology, biochemistry, measurement science and physical chemistry. You will also be encouraged to establish and maintain close ties to research in academic and government research communities.

We offer a competitive salary, benefits including tuition assistance and relocation, and a dynamic environment filled with learning and discovery beyond conventional scientific boundaries. Applicants must be authorized to work in the USA. For consideration please forward your CV to:

Human Resources, Dept. CR-SID, Unilever Research US, 45 River Road, Edgewater, NJ 07020 or E-Mail: job.mca@unilever.com . Please place only the letters "CR-SID" as the subject of your e-mail. Unilever is an Equal Opportunity Employer m/f/d/v.

### **Postdoctoral Fellows - Cancer and Developmental Biology**

- Two NIH-funded positions are available for fellows interested in studying the Hedgehog signaling pathway in development and disease using skin as a model system. One project centers on defining the function of the Hedgehog pathway during skin appendage morphogenesis (*Dev. Biol.* 205: 1-9, 1999); a second project focuses on understanding how deregulated activation of this pathway gives rise to basal cell carcinomas (*Nature Genet.* 24: 216-7, 2000). Applicants should have a solid background in molecular and cell biology, with experience in transgenic animal models desirable but not required. Interested individuals should send a CV, letter of interest, and names of three references to: Dr. Andrzej Dlugosz, University of Michigan, Department of Dermatology and Comprehensive Cancer Center, 3310 CCGC, Box 0932, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932 Email: dlugosza@umich.edu. The University of Michigan is an Equal Opportunity Employer.



### **Bibliography:**

The Bibliography published in this issue covers the period September, 2002 through November, 2002. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. By its very nature, assignment of a reference to a particular category is arbitrary and we urge you to read through all categories to make sure you don't miss any pertinent to your field.

### **MELANINS, MELANOGENS & MELANOGENESIS**

- Akeo K, Hiramitsu T, Yorifuji H, Okisaka S: Membranes of retinal pigment epithelial cells in vitro are damaged in the phagocytotic process of the photoreceptor outer segment discs peroxidized by ferrous ions. *PIGM CELL RES* 15:341-347 (2002).
- Asakawa A, Inui A, Goto K, Yuzuriha H, Takimoto Y, Inui T, Katsuura G, Fujino MA, Meguid MM, Kasuga M: Effects of agouti-related protein, orexin and melanin-concentrating hormone on oxygen consumption in mice. *INT J MOL MED* 10:523-525 (2002).
- Bachner D, Kreienkamp HJ, Richter D: MIZIP, a highly conserved, vertebrate specific melanin-concentrating hormone receptor 1 interacting zinc-finger protein. *FEBS LETT* 526:124-128 (2002).
- Cohen RJJ, Wade PR, Gershon MD: Suppressiton of the melanogenic potential of mitgrating neural crest-derived cells by the branchial arches. *ANAT REC* 268:16-26 (2002).
- De Gregorio E, Han SJ, Lee WJ, Baek MJ, Osaki T, Kawabata SI, Lee BL, Iwanaga S, Lemaitre B, Brey PT: An immune-responsive serpin regulates the melanization cascade in *Drosophila*. *DEV CELL* 3:581-592 (2002).
- Diaz-Veliz G, Mora S, Dossi MT, Gomez P, Arriagada C, Montiel J, Aboitiz F, Segura-Aguilar J: Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. *PHARMACOL BIOCHEM BEHAV* 73:843-850 (2002).
- Double KL, Ben Shachar D, Youdim MBH, Zecca L, Riederer P, Gerlach M: Influence of neuromelanin on oxidative pathways within the human substantia nigra. *NEUROTOXICOL.TERATOL.* 24:621-628 (2002).
- Fujii R, Goda M, Oshima N: Mechanism by which an elevation of extracellular glucide concentration induces pigment aggregation in medaka melanophores. *MICROSC RES TECHNIQUE* 58:514-522 (2002).
- Fujii Y, Asahara M, Ichinoe M, Nakajima H: Fungal melanin inhibitor and related compounds from *Penicillium decumbens*. *PHYTOCHEMISTRY* 60:703-708 (2002).
- Jones K, Hughes J, Hong M, Jia Q, Orndorff S: Modulation of melanogenesis by aloesin: A competitive inhibitor of tyrosinase. *PIGM CELL RES* 15:335-340 (2002).
- Khaled M, Larribere L, Bille K, Aberdam E, Ortonne JP, Ballotti R, Bertolotto C: Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. *J BIOL CHEM* 277:33690-33697 (2002).
- La Porta CAM, Porro D, Comolli R: Higher levels of melanin and inhibition of cdk2 activity in primary human melanoma cells WM115 overexpressing nPKCdelta. *MELANOMA RES* 12:297-307 (2002).
- Lee SH, Choi SY, Kim H, Hwang JS, Lee BG, Gao JJ, Kim SY: Mulberroside F isolated from the leaves of *Morus alba* inhibits melanin biosynthesis. *BIOL PHARM BULL* 25:1045-1048 (2002).
- Lister JA: Development of pigment cells in the zebrafish embryo. *MICROSC RES TECHNIQUE* 58:435-441 (2002).
- Lucas-Elio P, Solano F, Sanchez-Amat A: Regulation of polyphenol oxidase activities and melanin synthesis in *Marinomonas mediterranea*: identification of ppoS, a gene encoding a sensor histidine kinase. *MICROBIOLOGY SGM* 148:2457-2466:2457-2466 (2002).
- Mathey A, Spitteller P, Steglich W: Draculone, a new anthraquinone pigment from the tropical lichen *Melanotheca cruenta*. *Z.NATURFORSCH.C* 57:565-567 (2002).

- Nagai N, Lee YJ, Nagaoka N, Gunduz M, Nakano K, Nojima T, Tsujigiwa H, Gunduz E, Siar CH, Nagatsuka H: Elemental sulphur and alkali elutable melanin detected in oral melanosis and malignant melanoma by energy-filtering transmission electron microscopy. *J ORAL PATHOL MED* 31:481-487 (2002).
- Nosanchuk JD, Gomez BL, Youngchim S, Diez S, Aisen P, Zancope-Oliveira RM, Restrepo A, Casadevall A, Hamilton AJ: Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. *INFEC IMMUNITY* 70:5124-5131 (2002).
- Oh H, Mun YJ, Im SJ, Lee SY, Song HJ, Lee HS, Woo WH: Cucurbitacins from *Trichosanthes kirilowii* as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. *PLANTA MED* 68:832-833 (2002).
- Quigley IK, Parichy DM: Pigment pattern formation in zebrafish: A model for developmental genetics and the evolution of form. *MICROSC RES TECHNIQUE* 58:442-455 (2002).
- Routaboul C, Denis A, Bohbot M: Proposal for a new UVA protection factor: use of an in vitro model of immediate pigment darkening. *EUROPEAN J DERMATOLOGY* 12:439-444 (2002).
- Spelt C, Quattrocchio F, Mol J, Koes R: ANTHOCYANIN1 of petunia controls pigment synthesis, vacuolar pH, and seed coat development by genetically distinct mechanisms. *PLANT CELL* 14:2121-2135 (2002).
- Sugimoto N: Morphological color changes in fish: Regulation of pigment cell density and morphology. *MICROSC RES TECHNIQUE* 58:496-503 (2002).
- Turkovskii II, Yurlova NA: The photochemical and surface-active properties of melanins isolated from some black fungi. *MICROBIOLOGY ENGL.TR.* 71:410-416 (2002).
- van dM, I, Blizzard L, Stankovich J, Ponsonby AL, Dwyer T: Misclassification due to body hair and seasonal variation on melanin density estimates for skin type using spectrophotometry. *J PHOTOCHEM PHOTOBIOLOG B BIOL* 68:45-52 (2002).
- van Duin D, Casadevall A, Nosanchuk JD: Melanization of *Cryptococcus neoformans* and *Histoplasma capsulatum* reduces their susceptibilities to amphotericin B and caspofungin. *ANTIMICROB AGENTS CHEMOTHER* 46:3394-3400 (2002).
- Wang HL, Breuil C: A second reductase gene involved in melanin biosynthesis in the sap-staining fungus *Ophiostoma floccosum*. *MOL GENET GENOMICS* 267:557-563 (2002).
- Wang QF, Liu HB, Szaniszlo PJ: Compensatory expression of five chitin synthase genes, a response to stress stimuli, in *Wangiella (Exophiala) dermatitidis*, a melanized fungal pathogen of humans. *MICROBIOLOGY SGM* 148:2811-2817:2811-2817 (2002).
- Wellbrock C, Gomez A, Scharl M: Melanoma development and pigment cell transformation in *Xiphophorus*. *MICROSC RES TECHNIQUE* 58:456-463 (2002).

### MELANOSOMES, MELANOCYTES & KERATINOCYTES

- Alajlan A, Alfadley A, Pedersen KT: Transfer of vitiligo after allogeneic bone marrow transplantation. *J AMER ACAD DERMATOL* 46:606-610 (2002).
- Au JSY, Huang JD: A tissue-specific exon of myosin Va is responsible for selective cargo binding in melanocytes. *CELL MOTILITY.CYTOSKEL.* 53:89-102 (2002).
- Bastian BC, Xiong J, Frieden IJ, Williams ML, Chou P, Busam K, Pinkel D, LeBoit PE: Genetic changes in neoplasms arising in congenital melanocytic nevi - Differences between nodular proliferations and melanomas. *AMER J PATHOL* 161:1163-1169 (2002).
- Bauer BS: The role of tissue expansion in the management of large congenital pigmented nevi of the forehead in the pediatric patient - Reply. *PLAST RECONSTR SURG* 110:1191-1192 (2002).
- Bergh K, Wentzel P, Stjernschantz J: Production of prostaglandin E2 by iridial melanocytes exposed to latanoprost acid, a prostaglandin F-2alpha analogue. *J OCUL PHARMACOL THERAPEUT* 18:391-400 (2002).

- Brown KL, Clark RJH: Analysis of pigmentary materials on the Vinland Map and tartar relation by Raman microprobe spectroscopy. *ANAL CHEM* 74:3658-3661 (2002).
- Carli P, Naldi L, Lovati S, La Vecchia C: The density of melanocytic nevi correlates with constitutional variables and history of sunburns: A prevalence study among Italian schoolchildren. *INT J CANCER* 101:375-379 (2002).
- Cesinaro AM, Natoli C, Grassadonia A, Tinari N, Iacobelli S, Trentini GP: Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. *J INVEST DERMATOL* 119:187-190 (2002).
- Chan J, Robinson ES, Yen IT, McCarrey JR: Absence of ras gene mutations in UV-induced malignant melanomas correlates with a dermal origin of melanocytes in *Monodelphis domestica*. *CANCER LETT* 184:73-80 (2002).
- Chaubal VA, Nair SS, Mojamdar MV: Type I gamma-GT mRNA is expressed in B16 melanoma and levels correlate with pigmentation. *PIGM CELL RES* 15:367-372 (2002).
- De Maziere AM, Muehlethaler K, van Donselaar E, Salvi S, Davoust J, Cerottini JC, Levy F, Slot JW, Rimoldi D: The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins. *TRAFFIC*. 3:678-693 (2002).
- Dean NR, Brennan J, Haynes J, Goddard C, Cooter RD: Immunohistochemical labeling of normal melanocytes. *APPL IMMUNOHISTOCHEM MOL MORP* 10:199-204 (2002).
- Ellison G, Klinowska T, Westwood RFR, Docter E, French T, Fox JC: Further evidence to support the melanocytic origin of MDA-MB-435. *J CLIN PATHOL MOL PATHOL* 55:294-299 (2002).
- Falcon-Perez JM, Starcevic M, Gautam R, Dell'Angelica EC: BLOC-1, a novel complex containing the pallidin and muted proteins involved in the biogenesis of melanosomes and platelet-dense granules. *J BIOL CHEM* 277:28191-28199 (2002).
- Fang D, Tsuji Y, Setaluri V: Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF. *NUCL ACID RES* 30:3096-3106 (2002).
- Ferrara G, Argenziano G, Soyer HP, Corona R, Sera F, Brunetti B, Cerroni L, Chimenti S, Shabrawi-Caelen L, Ferrari A, Hofmann-Wellenhof R, Kaddu S, Piccolo D, Scalvenzi M, Staibano S, Wolf IH, De Rosa G: Dermoscopic and histopathologic diagnosis of equivocal melanocytic skin lesions - An interdisciplinary study on 107 cases. *CANCER* 95:1094-1100 (2002).
- Fodor J: Correspondence re: Y. Kuniwa et al., - Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. *Cancer Res.*, 61: 7900-7907, 2001. *CANCER RES* 62:4836 (2002).
- Furuya R, Akiu S, Ideta R, Naganuma M, Fukuda M, Hirobe T: Changes in the proliferative activity of epidermal melanocytes in serum-free primary culture during the development of ultraviolet radiation B-induced pigmented spots in hairless mice. *PIGM CELL RES* 15:348-356 (2002).
- Geissinger E, Weisser C, Fischer P, Scharl M, Wellbrock C: Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. *CANCER RES* 62:4820-4828 (2002).
- Gulec AT, Seckin D, Saray Y, Sarifakioglu E, Moray G, Colak T: Number of acquired melanocytic nevi in renal transplant recipients as a risk factor for melanoma. *TRANSPLANT PROC* 34:2136-2138 (2002).
- Hale LP: Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes. *J INVEST DERMATOL* 119:464-470 (2002).
- Hedley JD, Mumby PJ: Biological and remote sensing perspectives of pigmentation in coral reef organisms. *ADVANCES IN MARINE BIOLOGY*, VOL.43. 277-317:317 (2002).
- Hill C, Dunbar JC: The effects of acute and chronic alpha melanocyte stimulating hormone (alphaMSH) on cardiovascular dynamics in conscious rats. *PEPTIDES* 23:1625-1630 (2002).
- Hirobe T: Role of leukemia inhibitory factor in the regulation of the proliferation and differentiation of neonatal mouse epidermal melanocytes in culture. *J CELL PHYSIOL* 192:315-326 (2002).

- Hirobe T, Furuya R, Akiu S, Ifuku O, Fukuda M: Keratinocytes control the proliferation and differentiation of cultured epidermal melanocytes from ultraviolet radiation B-induced pigmented spots in the dorsal skin of hairless mice. *PIGM CELL RES* 15:391-399 (2002).
- Horn D, Happle R, Neitzel H, Kunze J: Pigmentary mosaicism of the hyperpigmented type in two half-brothers. *AMER J MED GENET* 112:65-69 (2002).
- Jamal S, Schneider RJ: UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. *J CLIN INVEST* 110:443-452 (2002).
- Kawakami Y, Kiniwa Y: Correspondence re: Y. Kiniwa et al., - Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. *Cancer Res.*, 61: 7900-7907, 2001 - Reply. *CANCER RES* 62:4836-4837 (2002).
- Kimler VA, Taylor JD: Morphological studies on the mechanisms of pigmentary organelle transport in fish xanthophores and melanophores. *MICROSC RES TECHNIQUE* 58:470-480 (2002).
- Kittler H: Follow-up of melanocytic skin lesions with digital dermoscopy: Risks and benefits. *ARCH DERMATOL* 138:1379 (2002).
- Koenigsmann M, Jautzke G, Unger M, Theallier-Janko A, Wiegel T, Stoltenburg-Didinger G: June 2002: 57-year-old male with leptomeningeal and liver tumors - Diagnosis - Metastasizing, melanocytic leptomeningeal tumor with histomorphological characteristics of a melanocytoma. *BRAIN PATHOL* 12:519-+ (2002).
- Kopp A, Carroll SB: Fruitflies - Pigmentation and mate choice in *Drosophila* - Reply. *NATURE* 419:360 (2002).
- Llopart A, Elwyn S, Coyne JA: Fruitflies - Pigmentation and mate choice in *Drosophila*. *NATURE* 419:360 (2002).
- Lohmann CM, Iversen K, Jungbluth AA, Berwick M, Busam KJ: Expression of melanocyte differentiation antigens and Ki-67 in nodal nevi and comparison of Ki-67 expression with metastatic melanoma. *AMER J SURG PATHOL* 26:1351-1357 (2002).
- Loumbourdis NS, Vogiatzis AK: Impact of cadmium on liver pigmentary system of the frog *Rana ridibunda*. *ECOTOXICOL ENVIRON SAFETY* 53:52-58 (2002).
- Ni Z, Mu Y, Gulati O: Treatment of melasma with Pycnogenol((R)). *PHYTOTHER.RES* 16:567-571 (2002).
- Niwa T, Mochii M, Nakamura A, Shiojiri N: Plumage pigmentation and expression of its regulatory genes during quail development - histochemical analysis using Bh (black at hatch) mutants. *MECH DEVELOP* 118:139-146 (2002).
- Pizzichetta MA, Talamini R, Piccolo D, Trevisan G, Veronesi A, Carbone A, Soyer HP: Interobserver agreement of the dermoscopic diagnosis of 129 small melanocytic skin lesions. *TUMORI* 88:234-238 (2002).
- Riccioni L, Cenacchi G, Ragazzini T, Collina G: Follicular baso-squamous melanocytic tumour of the skin. *HISTOPATHOLOGY* 41:337-341 (2002).
- Ronger S, Touzet S, Ligeron C, Balme B, Viillard AM, Barrut D, Colin C, Thomas L: Dermoscopic examination of nail pigmentation. *ARCH DERMATOL* 138:1327-1333 (2002).
- Satyamoorthy K, Li G, Van Belle PA, Elder DE, Herlyn M: A versatile method for the removal of melanin from ribonucleic acids in melanocytic cells. *MELANOMA RES* 12:449-452 (2002).
- Scott G: Rac and Rho: The story behind melanocyte dendrite formation. *PIGM CELL RES* 15:322-330 (2002).
- Shang J, Schwarz C, Ruderisch HS, Hertting T, Orfanos CE, Tebbe B: Effects of UVA and L-ascorbic acid on nuclear factor- $\kappa$ B in melanocytes and in HaCaT keratinocytes. *SKIN PHARMACOL APPL SKIN PHYS* 15:353-359 (2002).
- Shang J, Eberle J, Geilen CC, Hossini AM, Fecker LF, Orfanos CE, Tebbe B: The role of nuclear factor- $\kappa$ B and melanogenesis in tumor necrosis factor- $\alpha$ -induced apoptosis of normal human melanocytes. *SKIN PHARMACOL APPL SKIN PHYS* 15:321-329 (2002).

- Simonetti O, Lucarini G, Brancorsini D, Nita P, Bernardini ML, Biagini G, Offidani A: Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. *CANCER* 95:1963-1970 (2002).
- Skold HN, Norstrom E, Wallin M: Regulatory control of both microtubule- and actin- dependent fish melanosome movement. *PIGM CELL RES* 15:357-366 (2002).
- Skold HN, Aspengren S, Wallin M: The cytoskeleton in fish melanophore melanosome positioning. *MICROSC RES TECHNIQUE* 58:464-469 (2002).
- Sturm RA: Skin colour and skin cancer - MC1R, the genetic link. *MELANOMA RES* 12:405-416 (2002).
- Suga Y, Ikejima A, Matsuba S, Ogawa H: Medical Pearl: DHA application for camouflaging segmental vitiligo and piebald lesions. *J AMER ACAD DERMATOL* 47:436-438 (2002).
- Sutton R, Gordon-Thomson C, Cree IA, Mason RS, Moore GPM: Tyr-TGFalpha transgenic mice develop ocular melanocytic lesions. *MELANOMA RES* 12:435-439 (2002).
- Testorf MF, Oberg PA, Iwasaka M, Ueno S: Melanophore aggregation in strong static magnetic fields. *BIOELECTROMAGNETICS* 23:444-449 (2002).
- Tjioe M, Gerritsen MJP, Juhlin L, Van de Kerkhof PCM: Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. *ACTA DERMATO VENEREOL* 82:369-372 (2002).
- Tosti A, Argenziano G: Dermoscopy allows better management of nail pigmentation. *ARCH DERMATOL* 138:1369-1370 (2002).
- Tsukamoto K, Osada A, Kitamura R, Ohkouchi M, Shimada S, Takayama O: Approaches to repigmentation of vitiligo skin: New treatment with ultrasonic abrasion, seed-grafting and psoralen plus ultraviolet a therapy. *PIGM CELL RES* 15:331-334 (2002).
- Ujihara M, Kamakura T, Ikeda M, Kodama H: Dowling-Degos disease associated with squamous cell carcinomas on the dappled pigmentation. *BRIT J DERMATOL* 147:568-571 (2002).
- Unlu RE, Tekin F, Sensoz O: The role of tissue expansion in the management of large congenital pigmented nevi of the forehead in the pediatric patient. *PLAST RECONSTR SURG* 110:1191 (2002).
- Wagner JK, Jovel C, Norton HL, Parra EJ, Shriver MD: Comparing quantitative measures of erythema, pigmentation and skin response using reflectometry. *PIGM CELL RES* 15:379-384 (2002).
- Wagner JK, Parra EJ, Norton HL, Jovel C, Shriver MD: Skin responses to ultraviolet radiation: Effects of constitutive pigmentation, sex, and ancestry. *PIGM CELL RES* 15:385-390 (2002).
- Wang LT, Demirs JT, Pathak MA, Gonzalez S: Real-time, in vivo quantification of melanocytes by near- infrared reflectance confocal microscopy in the guinea pig animal model. *J INVEST DERMATOL* 119:533-535 (2002).
- Wang YF, Hu DN, McCormick SA, Savage HE, O'Rourke J: Tissue plasminogen activator is released into cultured medium by cultured human uveal melanocytes. *PIGM CELL RES* 15:373-378 (2002).
- Waterman EA, Kemp EH, Gawkrödger DJ, Watson PF, Weetman AP: Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. *CLIN EXP IMMUNOL* 129:527-532 (2002).
- Wilkie AL, Jordan SA, Jackson IJ: Neural crest progenitors of the melanocyte lineage: coat colour patterns revisited. *DEVELOPMENT* 129:3349-3357 (2002).
- Zaenglein AL, Heintz P, Kamino H, Zisblatt M, Orlow SJ: Congenital Spitz nevus clinically mimicking melanoma. *J AMER ACAD DERMATOL* 47:441-444 (2002).

**MELANOMA & METASTASIS**

- Agarwala SS, Hellstrand K, Naredi P: Interleukin-2 and histamine dihydrochloride in metastatic melanoma. *J CLIN ONCOL* 20:3558-3559 (2002).
- Alazraki N, Glass EC, Castronovo F, Olmos RAV, Podoloff D: Procedure guideline for lymphoscintigraphy and the use of Intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. *J NUCL MED* 43:1414-1418 (2002).
- Ali FS, Harris PA, Butler PEM: Ambiguity in the U.K. guidelines for the management of cutaneous melanoma. *BRIT J DERMATOL* 147:835-836 (2002).
- Altomonte M, Maio M: European approach to antibody-based immunotherapy of melanoma. *SEMIN ONCOL* 29:471-478 (2002).
- Amirkhosravi A, Amaya M, Desai H, Francis JL: Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. *BLOOD COAGULAT FIBRINOL* 13:505-512 (2002).
- Artym VV, Petty HR: Molecular proximity of Kv1.3 voltage-gated potassium channels and beta(1)-integrins on the plasma membrane of melanoma cells: Effects of cell adherence and channel blockers. *J GEN PHYSIOL* 120:29-37 (2002).
- Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D: Metastatic melanoma: Chemotherapy. *SEMIN ONCOL* 29:427-445 (2002).
- Barthomeuf C, Debiton E, Mshvildadze V, Kemertelidze E, Balansard G: In vitro activity of hederacolchisid A(1) compared with other saponins from *Hedera colchica* against proliferation of human carcinoma and melanoma cells. *PLANTA MED* 68:672-675 (2002).
- Bastias J, Wei MX, Huynh R, Chaubet F, Jozefonvicz J, Crepin M: Anti-proliferative and antitumoral activities of a functionalized dextran (CMDDBJ) on the 1205 L-U human tumor melanoma cells. *ANTICANCER RES* 22:1603-1613 (2002).
- Bechrakis NE, Bornfeld N, Zoller I, Foerster MH: Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. *OPHTHALMOLOGY* 109:1855-1861 (2002).
- Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. *J CLIN ONCOL* 20:4169-4180 (2002).
- Berd D, Sato T, Mastrangelo MJ: Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed- type hypersensitivity responses. *CANCER IMMUNOL IMMUNOTHER* 51:320-326 (2002).
- Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B: Incidence of uveal melanoma in Sweden from 1960 to 1998. *INVEST OPHTHALMOL VISUAL SCI* 43:2579-2583 (2002).
- Bishop JAN, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DLL, Anstey AV, Barlow RJ, Cox NH: High-dose interferon, sentinel lymph node biopsy and the U.K. guidelines for cutaneous melanoma: reply from authors. *BRIT J DERMATOL* 147:834-835 (2002).
- Bishop JAN, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DLL, Anstey AV, Barlow RJ, Cox NH: Ambiguity in the U.K. guidelines for the management of cutaneous melanoma: reply from authors. *BRIT J DERMATOL* 147:836-837 (2002).
- Bishop JAN, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DLL, Anstey AV, Barlow RJ, Cox NH: Staging investigations and the U.K. guidelines for cutaneous melanoma: reply from authors. *BRIT J DERMATOL* 147:838 (2002).
- Biswas J, Agarwal M, Krishnakumar S, Shanmugam MP: Uveal melanoma: Finland v India. *BRIT J OPHTHALMOL* 86:1193 (2002).



- Braun RD, Abbas A, Bukhari SO, Wilson W: Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid. *INVEST OPHTHALMOL VISUAL SCI* 43:3045-3052 (2002).
- Brenner AV, Lubin JH, Calista D, Landi MT: Instrumental measurements of skin color and skin ultraviolet light sensitivity and risk of cutaneous malignant melanoma: A case-control study in an Italian population. *AMER J EPIDEMIOLOG* 156:353-362 (2002).
- Buonomo O, Felici A, Granai AV, Piccirillo R, Carino ND, Guadagni F, Mariotti S, Orlandi A, Tiplaldi G, Cipriani C, Chimenti S, Cervelli V, Casciani C, Roselli M: Sentinel lymphadenectomy in cutaneous melanoma. *TUMORI* 88:S49-S51 (2002).
- Busam KJ, Charles C, Lohmann CM, Marghoob A, Goldgeier M, Halpern AC: Detection of intraepidermal malignant melanoma in vivo by confocal scanning laser microscopy. *MELANOMA RES* 12:349-355 (2002).
- Cafiero F, Gipponi M, Di Somma C, Solari N, Peressini A, Gliori S, Bassetti C, Spina B, Nicolo G, Schenone F, Castagnola F, Queirolo P, Sertoli MR: The role of sentinel lymph node biopsy in patients with stage VII cutaneous melanoma. The clinical experience at the National Cancer Research Institute of Genoa, Italy. *TUMORI* 88:S55-S56 (2002).
- Caprio MG, Carbone G, Bracigliano A, Acampa W, Mainolfi C, Molea G, Salvatore M: Sentinel lymph node detection by lymphoscintigraphy in malignant melanoma. *TUMORI* 88:S43-S45 (2002).
- Caraco C, Chiofalo MG, Niro J, Ascierio PA, Botti G, Lastoria S, Mozzillo N: Sentinel lymph node biopsy to stage patients with cutaneous melanoma at the National Cancer Institute of Naples. Results from 240 sentinel node biopsies. *TUMORI* 88:S12-S13 (2002).
- Carcoforo P, Soliani G, Bergossi L, Basaglia E, Virgili AR, Pagani W, Pozza E, Feggi LM: Reliability and accuracy of sentinel node biopsy in cutaneous malignant melanoma. *TUMORI* 88:S14-S16 (2002).
- Cattell E, Kelly C, Middleton MR: Brain Metastases in melanoma: A European perspective. *SEMIN ONCOL* 29:513-517 (2002).
- Cen DZ, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL: Disulfiram induces apoptosis in human melanoma cells: A redox-related process. *MOL CANCER THER* 1:197-204 (2002).
- Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ: Clinical results using biochemotherapy as a standard of care in advanced melanoma. *MELANOMA RES* 12:381-387 (2002).
- Char DH, Kroll S, Phillips TL, Quivey JM: Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. *OPHTHALMOLOGY* 109:1850-1854 (2002).
- Chen X, Maniotis AJ, Majumdar D, Pe'er J, Folberg R: Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. *INVEST OPHTHALMOL VISUAL SCI* 43:2533-2539 (2002).
- Chen YL, Wang JY, Chen SH, Yang BC: Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behaviour. *BRIT J CANCER* 87:359-365 (2002).
- Cheng SF, Alfonso-Jaume MA, Mertens PR, Lovett DH: Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). *BIOCHEM J* 366:807-816:807-816 (2002).
- Cheung KJ, Li G: P33(ING1) enhances UVB-induced apoptosis in melanoma cells. *EXP CELL RES* 279:291-298 (2002).
- Cohen L, Parker PA, Sterner J, de Moor C: Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. *MELANOMA RES* 12:505-511 (2002).

- Conacci-Sorrell ME, Ben Yedidia T, Shtutman M, Feinstein E, Einat P, Ben Ze'ev A: Nr-CAM is a target gene of the beta-catenin/LEF-1 in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. *GENE DEVELOP* 16:2058-2072 (2002).
- D'Silva NJ, Kurago Z, Polverini PJ, Hanks CT, Paulino AF: Malignant melanoma of the oral mucosa in a 17-year-old adolescent girl. *ARCH PATHOL LAB MED* 126:1110-1113 (2002).
- De Vries E, Dore JF, Autier P, Eggermont AMM, Coebergh JWW: Patients' perception of the cause of their melanoma differs from that of epidemiologists. *BRIT J DERMATOL* 147:388-389 (2002).
- de Zoeten EF, Markovic D, Cohen EP: An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both syngeneic and allogeneic MHC-determinants. *GENE THERAPY* 9:1163-1172 (2002).
- Debiton E, Glasser AL, Marchenay C, Rolhion C, Maurizis JC, Madelmont JC: Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-benzyl-N2-acetylguanosine increases chloroethylnitrosourea-induced apoptosis in Mer(+) human melanoma cells. *MELANOMA RES* 12:417-427 (2002).
- Deichmann M, Mollenhauer J, Helmke B, Thome M, Hartschuh W, Poustka A, Naher H: Analysis of losses of heterozygosity of the candidate tumour suppressor gene DMBT1 in melanoma resection specimens. *ONCOLOGY BASEL* 63:166-172 (2002).
- Demirci H, Shields CL, Shields JA, Eagle RC, Honavar SG: Diffuse iris melanoma - A report of 25 cases. *OPHTHALMOLOGY* 109:1553-1560 (2002).
- Di Loreto S, Spadea L, Cencioni S, Balestrazzi E, Adorno D, Cervetto L, Bisti S: Correlation between ERG changes and FGF2 mRNA up-regulation in patients with choroidal melanoma. *EXP EYE RES* 75:217-225 (2002).
- DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, Stern SL, Morton DL: Enhanced humoral immune response correlates with improved disease-free and overall survival in American joint committee on cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. *J CLIN ONCOL* 20:3242-3248 (2002).
- Douglas JG, Margolin K: The treatment of brain Metastases from malignant melanoma. *SEMIN ONCOL* 29:518-524 (2002).
- Dresel A, Kuhn JA, McCarty TM: Sentinel node biopsy site used as full thickness skin graft donor for cutaneous melanoma. *AMER J SURG* 184:176-178 (2002).
- Duan ZG, Shen HB, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Spitz MR, Wei QY: DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. *CANCER EPIDEM BIOMARKER PREV* 11:1142-1143 (2002).
- Edmunds SC, Kelsell DP, Hungerford JL, Cree IA: Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. *INVEST OPHTHALMOL VISUAL SCI* 43:2845-2851 (2002).
- Eggermont AMM, Gore M: European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. *SEMIN ONCOL* 29:382-388 (2002).
- Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA: Pegylated arginine deiminase (ADI-SS PEG(20,000) (mw)) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. *CANCER RES* 62:5443-5450 (2002).
- Feng Y, Shi J, Goldstein AM, Tucker MA, Nelson MA: Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34(CDC2)-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families (vol 99, pg 834, 2002). *INT J CANCER* 100:733-734 (2002).
- Flaherty LE, Gadgeel SM: Biochemotherapy of melanoma. *SEMIN ONCOL* 29:446-455 (2002).
- Gamel JW, George SL, Edwards MJ, Seigler HF: The long-term clinical course of patients with cutaneous melanoma. *CANCER* 95:1286-1293 (2002).
- Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, Wohlrab W, Heinemann SH: Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. *J MEMBRANE BIOL* 188:137-149 (2002).

- Geller AC, Sober AJ, Zhang Z, Brooks DR, Miller DR, Halpern A, Gilchrest BA: Strategies for improving melanoma education and screening for men age  $\leq$  50 years - Findings from the American Academy of Dermatology National Skin Cancer Screening Program. *CANCER* 95:1554-1561 (2002).
- Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK: Melanoma incidence and mortality among US whites, 1969- 1999. *JAMA J AM MED ASSN* 288:1719-1720 (2002).
- Georgieva J, Milling A, Orfanos CE, Geilen CC: Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. *MELANOMA RES* 12:309-317 (2002).
- Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, Tsoutsos D, Panagiotou P, Ioannovich J, Loukopoulos D: Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. *BRIT J CANCER* 87:181-186 (2002).
- Grob JJ: The debate over diagnostic accuracy in melanoma: Dermatologists or general practitioners? *ARCH DERMATOL* 138:1251-1252 (2002).
- Groisman GM, Arnar M, Schafer I: The histiocytic marker PG-M1 is helpful in differentiating histiocytes and histiocytic tumors from melanomas. *APPL IMMUNOHISTOCHEM MOL MORP* 10:205-209 (2002).
- Gruss C, Geissler A, Schalke B, Landthaler M, Stolz W: Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation. *MELANOMA RES* 12:403-404 (2002).
- Guillaume-Rousselet N, Jean D, Frade R: Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells. *BIOCHEM J* 367:219-227:219-227 (2002).
- Hammer ME, Margo CE: Unilateral multifocal uveal melanoma with occult ring melanoma. *ARCH OPHTHALMOL* 120:1090-1091 (2002).
- Han JS, Storck CW, Wachsberger PR, Leeper DB, Berd D, Wahl ML, Coss RA: Acute extracellular acidification increases nuclear associated protein levels in human melanoma cells during 42degreesC hyperthermia and enhances cell killing. *INT J HYPERTHER* 18:404-415 (2002).
- Harbour JW, Worley L, Ma DD, Cohen M: Transducible peptide therapy for uveal melanoma and retinoblastoma. *ARCH OPHTHALMOL* 120:1341-1346 (2002).
- Hazan C, Melzer K, Panageas KS, Li E, Kamino H, Kopf A, Cordon-Cardo C, Osman I, Polsky D: Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. *CANCER* 95:634-640 (2002).
- Heenan PJ, Taran JM: Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis - Reply. *CANCER* 95:672-673 (2002).
- Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ: Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. *J CLIN ONCOL* 20:4181-4190 (2002).
- Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D: Primary staging and follow-up in melanoma patients monocenter evaluation of methods, costs and patient survival. *BRIT J CANCER* 87:151-157 (2002).
- Holland R, Harvey I: Adult vs childhood susceptibility to melanoma: Is there a difference? *ARCH DERMATOL* 138:1234-1235 (2002).
- Houghton AN, Polsky D: Focus on melanoma. *CANCER CELL* 2:275-278 (2002).
- Hu Q, Bally MB, Madden TD: Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. *NUCL ACID RES* 30:3632-3641 (2002).
- Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002). *J CLIN ONCOL* 20:3361 (2002).

- Iervolino A, Trisciuglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D: Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1- mediated transcriptional activity. *FASEB J* 16:NIL (2002).
- Irwin N, Walker G, Hayward N, Irwin N, Walker G, Hayward N: Lack of TTC4 mutations in melanoma. *J INVEST DERMATOL* 119:186-187 (2002).
- Joo SS, Kim MS, Oh WS, Lee DI: Enhancement of NK cytotoxicity, antimetastasis and elongation effect of survival time in B16-F10 melanoma cells by oregonin. *ARCH PHARM RESEARCH* 25:493-499 (2002).
- Journee-de Korver JG, Keunen JEE: Thermotherapy in the management of choroidal melanoma. *PROG RETIN.EYE RES* 21:303-317 (2002).
- Juzenas P, Juzeniene A, Stakland S, Iani V, Moan J: Photosensitizing effect of protoporphyrin IX in pigmented melanoma of mice. *BIOCHEM BIOPHYS RES COMMUN* 297:468-472 (2002).
- Keilholz U, Gore ME: Biochemotherapy for advanced melanoma. *SEMIN ONCOL* 29:456-461 (2002).
- Kelley ST, Menon C, Buerk DG, Bauer TW, Fraker DL: Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. *SURGERY* 132:252-258 (2002).
- Khoshyomn S, Braff SP, McKenzie MA, Florman JE, Pendlebury WW, Penar PL: Metastatic intraventricular melanoma - Case illustration. *J NEUROSURG* 97:726 (2002).
- Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R: Immunomodulatory effects of high-dose and lowdose interferon alpha2b in patients with high-risk resected melanoma - The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690. *CANCER* 95:1101-1112 (2002).
- Kiser AC, Egan TM: Metastatic melanoma to the pleural space. *ANN THORAC.SURG* 74:1257 (2002).
- Koduri J, Baumann MA: Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients. *J CLIN ONCOL* 20:3560 (2002).
- Krause M, Kwong KK, Xiong J, Gragoudas ES, Young LHY: MRI of blood volume and cellular uptake of superparamagnetic iron in an animal model of choroidal melanoma. *OPHTHALMIC RES* 34:241-250 (2002).
- Krause SW, Neumann T, Soruri A, Mayer S, Peters JH, Andreesen R: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. *J IMMUNOTHER* 25:421-428 (2002).
- Kuniyasu H, Chihara Y, Kubozoe T, Takahashi T: Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer. *INT J MOL MED* 10:333-337 (2002).
- Kunz M, Koczan D, Ibrahim SM, Gillitzer R, Gross G, Thiesen HJ: Differential expression of thrombospondin 2 in primary and metastatic malignant melanoma. *ACTA DERMATO VENEREOL* 82:163-169 (2002).
- Kurokawa T, Fischer K, Bertz H, Hoegerle S, Finke J, Mackensen A: In vitro and in vivo characterization of graft-versus- tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. *INT J CANCER* 101:52-60 (2002).
- Lawton G, Rasque H, Ariyan S: Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. *J AMER COLL SURGEONS* 195:339-351 (2002).
- Lee KJ, Mao SL, Sun CZ, Gao CS, Blixt O, Arrues S, Hom LG, Kaufmann GF, Hoffman TZ, Coyle AR, Paulson J, Felding-Habermann B, Janda KD: Phage-display selection of a human single-chain Fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)- carbohydrate antigen. *J AM CHEM SOC* 124:12439-12446 (2002).
- Lens MB, Dawes M: Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma - Reply. (

- Lens MB, Dawes M, Newton-Bishop JA, Goodacre T: Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. *BRIT J SURG* 89:1223-1227 (2002).
- Lens MB, Dawes M, Goodacre T, Bishop JAN: Excision margins in the treatment of primary cutaneous melanoma - A systematic review of randomized controlled trials comparing narrow vs wide excision. *ARCH SURG* 137:1101-1105 (2002).
- Li LXL, Crotty KA, Palmer AA, Kril JJ, Stankovic R, Scolyer RA, McCarthy SW: Differentiating benign nevi from malignant melanoma using DNA microdensitometry and karyometry and maturation - A zonal comparison, correlation and multivariate analysis. *ANAL QUANT CYTOL HISTOL* 24:234-243 (2002).
- Li Y, McClay EF: Systemic chemotherapy for the treatment of metastatic melanoma. *SEMIN ONCOL* 29:413-426 (2002).
- Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, Kennedy R, Errington F, Harrington KJ, Melcher A, Vile R: Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. *CANCER RES* 62:5495-5504 (2002).
- Longo I, Sanchez-Mateos P, Lazaro P, Londo N: Azoospermia in a patient receiving interferon alpha for a stage III melanoma. *ACTA DERMATO VENEREOL* 82:389-390 (2002).
- Lumbroso L, Sigal-Zafrani B, Jouffroy T, Levy C, Rodriguez J, Desjardins L: Late malignant melanoma after treatment of rhabdomyosarcoma of the orbit during childhood. *ARCH OPHTHALMOL* 120:1087-1090 (2002).
- Lutzky J, Gonzalez-Angulo AM, Orzano JA: Antibody-based Vaccines for the treatment of melanoma. *SEMIN ONCOL* 29:462-470 (2002).
- Ma S, Egyhazi S, Martenhed G, Ringborg U, Hansson J: Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine- based chemotherapy. *MELANOMA RES* 12:335-342 (2002).
- Maccauro M, Gallino F, Aliberti G, Savelli G, Castellani MR, Villano C, Baio SM, Goilo AET, Belli F, Mansi L, Bombardieri E: Role of lymphoscintigraphy and intraoperative gamma probe guided sentinel node biopsy in head and neck melanomas. *TUMORI* 88:S22-S24 (2002).
- MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, Doherty V, Vestey J: Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. *LANCET* 360:587-591 (2002).
- Mandrizzato S, Rossi E, Bernardi F, Tosello V, Macino B, Basso G, Chiarion-Sileni V, Rossi CR, Montesco C, Zanovello P: Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. *J IMMUNOL* 169:4017-4024 (2002).
- Maniotis AJ, Chen X, Garcia C, DeChristopher PJ, Wu D, Pe'er J, Folberg R: Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. *LAB INVEST* 82:1031-1043 (2002).
- Manne J, Mastrangelo MJ, Sato T, Berd D: TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. *J IMMUNOL* 169:3407-3412 (2002).
- Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR: Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. *MELANOMA RES* 12:465-469 (2002).
- Matsumoto K, Takahashi K, Yoshiki A, Kusakabe M, Ariga H: Invasion of melanoma in double knockout mice lacking tenascin-X and tenascin-C. *JPN J CANCER RES* 93:968-975 (2002).
- Matsushita Y, Hatta N, Wakamatsu K, Takehara K, Ito S, Takata M: Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. *MELANOMA RES* 12:319-323 (2002).
- Maza S, Valencia R, Geworski L, Zander A, Drager E, Winter H, Sterry W, Munz DL: Temporary shielding of hot spots in the drainage areas of cutaneous melanoma improves accuracy of

- lymphoscintigraphic sentinel lymph node diagnostics. *EUR J NUCL MED MOL IMAGING* 29:1399-1402 (2002).
- McCart JA, Wang ZH, Xu H, Hu Y, Park B, Alexander HR, Bartlett DL: Development of a melanoma-specific adenovirus. *MOL THER* 6:471-480 (2002).
- McClay EF, Maio M: Melanoma: American and European perspectives on diagnosis and treatment. *SEMIN ONCOL* 29:306-307 (2002).
- McClay EF: Adjuvant therapy for patients with high-risk malignant melanoma. *SEMIN ONCOL* 29:389-399 (2002).
- McCurdy DK, Tai LQ, Imfeld KL, Schwartz M, Zaldivar F, Berman MA: Expression of melanoma antigen gene by cells from inflamed joints in juvenile rheumatoid arthritis. *J RHEUMATOL* 29:2219-2224 (2002).
- Mendilcioglu I, Zorlu CG, Pestereli HE, Karaveli S, Trak B: Vulvar malignant melanoma following radiotherapy for cervical cancer. *MELANOMA RES* 12:521-522 (2002).
- Meyer T, Hauschild A, Kromminga A, Hartleb J, Arndt R, Christophers E, Stockfleth E: Clinical evaluation of 5-S-cysteinyl-dopa testing using a new and optimized detection system as a tumour marker for malignant melanoma. *MELANOMA RES* 12:471-477 (2002).
- Middleton MR, Thatcher N, McMurry TBH, McElhinney RS, Donnelly DJ, Margison GP: Effect of O(6)-(4-bromophenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. *INT J CANCER* 100:615-617 (2002).
- Minev BR: Melanoma Vaccines. *SEMIN ONCOL* 29:479-493 (2002).
- Mitchell MS, Darrah D, Stevenson L: Therapy of melanoma with allogeneic melanoma lysates alone or with interferon- $\alpha$ . *CANCER INVEST* 20:759-768 (2002).
- Montero JL, Muntane J, de las HS, Ortega R, Fraga E, De la MM: Acute liver failure caused by diffuse hepatic melanoma infiltration. *J HEPATOL* 37:540-541 (2002).
- Morrison C, Young DC, Wakely PE: Cytopathology of malignant melanoma in conventional and liquid-based smears. *AMER J CLIN PATHOL* 118:435-441 (2002).
- Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DSB, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM: Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. *ANN SURG* 236:438-449 (2002).
- Mouawad R, Antoine EC, Gil-Delgado M, Khayat D, Soubrane C: Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy. *MELANOMA RES* 12:343-348 (2002).
- Mueller AJ, Maniotis AJ, Freeman WR, Bartsch DU, Schaller UC, Bergeron-Lynn G, Cheng LY, Taskintuna I, Chen X, Kan-Mitchell J, Folberg R: An orthotopic model for human uveal melanoma in SCID mice. *MICROVASCULAR RES* 64:207-213 (2002).
- Murata T, Imai T, Hoshino KI, Kato M, Tanigawa K, Higuchi T, Kozuka Y, Inoue R, Watanabe M, Shiraishi T, Takubo K: Esophageal anthracosis: Lesion mimicking malignant melanoma. *PATHOL INT* 52:488-491 (2002).
- Nagi C, O'Grady TC, Izadpanah A: Mohs micrographically controlled surgery and the treatment of malignant melanoma. *SEMIN ONCOL* 29:336-340 (2002).
- Okubo Y, Hamada J, Takahashi Y, Tada M, Tsutsumida A, Furuuchi K, Aoyama T, Sugihara T, Moriuchi T: Transduction of HOXD3-antisense into human melanoma cells results in decreased invasive and motile activities. *CLIN EXP METASTAS* 19:503-511 (2002).
- Ordonez JL, Saornil MA, Domingo E, Blanco G, Diebold Y, Morilla-Grasa A, Lopez R, Rabano G, Fernandez N, Mayo-Iscar A: The need for continuous immunosuppression with cyclosporin A to maintain an experimental model of uveal melanoma. *MELANOMA RES* 12:441-447 (2002).
- Osborne JE, Hutchinson PE: Vitamin D and systemic cancer: is this relevant to malignant melanoma? *BRIT J DERMATOL* 147:197-213 (2002).

- Palermo B, Campanelli R, Garbelli S, Mantovani S, della Cuna GR, Necker A, Manganoni AM, Carella G, Rivoltini L, Lantelme E, Giachino C: Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis. *MELANOMA RES* 12:491-498 (2002).
- Papoutsis M, Othman-Hassan K, Christ B, Patel K, Wilting J: Development of an arterial tree in C6 gliomas but not in A375 melanomas. *HISTOCHEMISTRY CELL BIOL* 118:241-249 (2002).
- Pennasilico GM, Arcuri PP, Laschena F, Potenza C, Ruatti P, Bono R, Sera F, Falappa P: Magnetic resonance imaging in the diagnosis of melanoma: in vivo preliminary studies with dynamic contrast-enhanced subtraction. *MELANOMA RES* 12:365-371 (2002).
- Pereira F, Carey W, Shibata H, Burnier MN, Wang B: Multiple nevoid malignant melanomas in a patient with AIDS: The role of proliferating cell nuclear antigen in the diagnosis. *J AMER ACAD DERMATOL* 47:S172-S174 (2002).
- Persson LM, Edgren MR, Stenerlow B, Lind BK, Hedlof I, Jernberg ARM, Meijer AE, Brahme A: Relative biological effectiveness of boron ions on human melanoma cells. *INT J RADIAT BIOL* 78:743-748 (2002).
- Pfahlberg A, Botev IN, Kolmel KF, Gefeller O: Vaccination and melanoma risk. *INT J CANCER* 102:96-97 (2002).
- Phillips WG: Sentinel lymph node biopsy and the U.K. guidelines for cutaneous melanoma. *BRIT J DERMATOL* 147:834 (2002).
- Poggi A, Rossi C, Casella N, Bruno C, Sturiale L, Dossi C, Naggi A: Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E-coli K5 polysaccharide. *SEMIN THROMB HEMOSTASIS*. 28:383-391 (2002).
- Pollock PM, Meltzer PS: A genome-based strategy uncovers frequent BRAF mutations in melanoma. *CANCER CELL* 2:5-7 (2002).
- Poser I, Golob M, Weidner M, Buettner R, Bosserhoff AK: Down-regulation of COOH-terminal binding protein expression in malignant melanomas leads to induction of MIA expression. *CANCER RES* 62:5962-5966 (2002).
- Punt CJA, Eggermont AMM: Adjuvant interferon for melanoma - Reply. *ANN ONCOL* 13:1320 (2002).
- Quirt I, Bodurtha A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N, Steward W, Eisenhauer E: Phase II study of marimastat (BB-2516) in malignant melanoma - A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. *INVEST NEW DRUG* 20:431-437 (2002).
- Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK: Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. *MELANOMA RES* 12:453-463 (2002).
- Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H: Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. *INT J CANCER* 100:580-585 (2002).
- Rees J: Functional polymorphism in EGF gene and malignant melanoma. *LANCET* 360:570 (2002).
- Reifenberger J, Knobbe CB, Wolter M, Blaschke B, Schulte KW, Pietsch T, Ruzicka T, Reifenberger G: Molecular genetic analysis of malignant melanomas for aberrations of the Wnt signaling pathway genes CTNNB1, APC, ICAT and BTRC. *INT J CANCER* 100:549-556 (2002).
- Ridolfi R, Nanni O: Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients - In reply. *J CLIN ONCOL* 20:3560-3561 (2002).
- Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC: The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. *BRIT J CANCER* 87:366-371 (2002).
- Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M: Isolated limb perfusion in locally advanced cutaneous melanoma. *SEMIN ONCOL* 29:400-409 (2002).

- Ruiter DJ, Spatz A, van den Oord JJ, Cook MG: Pathologic staging of melanoma. *SEMIN ONCOL* 29:370-381 (2002).
- Russell-Jones R, Healy C, Calonje E, Doherty M, Acland K: High-dose interferon and the U.K. guidelines for cutaneous melanoma. *BRIT J DERMATOL* 147:832-834 (2002).
- Sagiuchi T, Ishii K, Utsuki S, Asano Y, Tsukahara S, Kan S, Fujii K, Hayakawa K: Increased uptake of technetium-99m- hexamethylpropyleneamine oxime related to primary leptomeningeal melanoma. *AMER J NEURORADIOL.* 23:1404-1406 (2002).
- Satomi H, Wang BH, Fujisawa H, Otsuka F: Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. *CYTOKINE* 18:108-115 (2002).
- Sauter ER, Takemoto R, Litwin S, Herlyn M: p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. *CANCER GENE THERAPY* 9:807-812 (2002).
- Schadendorf D: Gene-based therapy of malignant melanoma. *SEMIN ONCOL* 29:503-512 (2002).
- Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG: A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. *CANCER RES* 62:5510-5516 (2002).
- Schmid-Wendtner MH, Baumert J, Stange J, Volkenandt M: Delay in the diagnosis of cutaneous melanoma: an analysis of 233 patients. *MELANOMA RES* 12:389-394 (2002).
- Schneider R: Dermoscopy in melanoma screening. *ARCH DERMATOL* 138:1378-1379 (2002).
- Scott RS, Vajdic CM, Armstrong BK, Ainsworth CJ, Meldrum CJ, Aitken JF, Krickler A: BRCA2 mutations in a population-based series of patients with ocular melanoma. *INT J CANCER* 102:188-191 (2002).
- Seal T, Mukherjee B: (+)-tiliarine, a selective in vitro inhibitor of human melanoma cells. *PHYTOTHER.RES* 16:596-599 (2002).
- Shaw HM, McCarthy WH, Scolyer RA: Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. *CANCER* 95:671-672 (2002).
- Shen J, Wallace AM, Bouvet M: The role of sentinel lymph node biopsy for melanoma. *SEMIN ONCOL* 29:341-352 (2002).
- Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J: Plaque radiotherapy for large posterior uveal melanomas ( $\geq 8$ -mm thick) in 354 consecutive patients. *OPHTHALMOLOGY* 109:1838-1849 (2002).
- Shoab T, Dunn R, Soutar DS: Staging investigations and the U.K. guidelines for cutaneous melanoma. *BRIT J DERMATOL* 147:837-838 (2002).
- Shors AR, Iwamoto S, Doody DR, Weiss NS: Relationship of uveal and cutaneous malignant melanoma in persons with multiple primary tumors. *INT J CANCER* 102:266-268 (2002).
- Spieth K, Risse J, Kaufmann R, Gille J: Challenging cases and diagnostic dilemmas - Case 3. Positron emission tomography scan mimicking lymph node metastases in a high-risk melanoma patient. *J CLIN ONCOL* 20:3349-3351 (2002).
- Srinivas P, Madhavan M, Ahamed I, Abraham E, Vijayalakshmy NR, Balam P: Nm23H1 and p53 proteins are differentially correlated to metastasis in breast carcinoma. *NEOPLASMA* 49:225-230 (2002).
- Stas M, Stroobants S, Dupont P, Gysen M, Van Hoe L, Garmyn M, Mortelmans L, De W, I: 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. *MELANOMA RES* 12:479-490 (2002).
- Staub E, Hinzmann B, Rosenthal A: A novel repeat in the melanoma-associated chondroitin sulfate proteoglycan defines a new protein family. *FEBS LETT* 527:114-118 (2002).
- Stein U, Jurchott K, Schlafke M, Hohenberger P: Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. *J CLIN ONCOL* 20:3282-3292 (2002).



- Suarez A, Fra J, Alonso R, Sanchez R, Lacave AJ, Gutierrez C: Optimization of the RT-PCR technique to detect melanoma cells in peripheral blood. *ANTICANCER RES* 22:1091-1095 (2002).
- Sulaimon SS, Kitchell BE, Ehrhart EJ: Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma. *J COMP PATHOL* 127:162-168 (2002).
- Tartaglione G, Potenza C, Caggiati A, Maggiore M, Gabrielli F, Migliano E, Pagan M, Concolino F, Ruatti P: Lymphatic mapping and sentinel node identification in squamous cell carcinoma and melanoma of the head and neck. *TUMORI* 88:S39-S41 (2002).
- Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB1\*0401(+) patients with renal cell carcinoma or melanoma. *J EXP MED* 196:619-628 (2002).
- Terada R, Ito S, Kobayashi M, Akama F, Tsujimura M, Ooe H: Anorectal melanoma: Successful treatment by surgical excision and combination chemoimmunotherapy. *HEPATO GASTROENTEROL* 49:1545-1548 (2002).
- Testori A, Mozzillo N: Surgical techniques of melanoma and sentinel node biopsy. *SEMIN ONCOL* 29:328-335 (2002).
- Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G, Schumacher U: Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. *EUR J CANCER* 38:1708-1716 (2002).
- Thome SD, Loprinzi CL, Heldebrant MP: Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. *MAYO CLIN PROC* 77:913-917 (2002).
- Thompson JA: The revised American Joint Committee on Cancer staging system for melanoma. *SEMIN ONCOL* 29:361-369 (2002).
- Tozer RG, Burdette-Radoux S, Berlangier K, Davis ML, Lohmann RC, Rusthoven JR, Wainman N, Zee B, Seymour L: A randomized phase II study of two schedules of bryostatin- 1 (NSC339555) in patients with advanced malignant melanoma - A National Cancer Institute of Canada Clinical Trials Group study. *INVEST NEW DRUG* 20:407-412 (2002).
- Ugurel S, Wagner A, Pfohler C, Tilgen W, Reinhold U: Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. *BRIT J DERMATOL* 147:621-624 (2002).
- Ulmer A, Metzger S, Fierlbeck G: Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta. *MELANOMA RES* 12:395-398 (2002).
- Vajdic CM, Krickler A, Giblin M, McKenzie J, Aitken J, Giles GG, Armstrong BK: Sun exposure predicts risk of ocular melanoma in Australia. *INT J CANCER* 101:175-182 (2002).
- van den Aardweg GJM, Naus NC, Verhoeven ACA, de Klein A, Luyten GPM: Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines. *INVEST OPHTHALMOL VISUAL SCI* 43:2561-2565 (2002).
- Villari D, Grosso M, Vitarelli E, Tuccari G, Barresi G: Melanoma markers in angiomyolipoma. *ARCH PATHOL LAB MED* 126:1157 (2002).
- Voigt H, Classen R: Computer vision and digital imaging technology in melanoma detection. *SEMIN ONCOL* 29:308-327 (2002).
- Voit C, Schoengen A, Schwurzer-Voit M, Weber L, Ulrich J, Sterry W, Proebstle TM: The role of ultrasound in detection and management of regional disease in melanoma patients. *SEMIN ONCOL* 29:353-360 (2002).
- Wack C, Kirst A, Becker JC, Lutz WK, Brocker EB, Fischer WH: Chemoimmunotherapy for melanoma with dacarbazine and 2,4- dinitrochlorobenzene elicits a specific T cell-dependent immune response. *CANCER IMMUNOL IMMUNOTHER* 51:431-439 (2002).
- Weeks DA, Hammar SP, Rader AE, Malott RL, Mierau GW: Sclerosing hemangioma of the lung in a young woman with cutaneous melanoma: The role of electron microscopy in preventing an erroneous diagnosis of metastasis. *ULTRASTRUCT PATHOL* 26:261-265 (2002).

- Weeraratna AT, Jiang YA, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. *CANCER CELL* 1:279-288 (2002).
- Wheatley K, Ives N, Hancock B, Gore M: Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. *J CLIN ONCOL* 20:4120-4121 (2002).
- Wheatley K, Ives N: Adjuvant interferon for melanoma. *ANN ONCOL* 13:1319-1320 (2002).
- Wheatley K, Ives N, Hancock B, Gore MB: Interferon as adjuvant treatment for melanoma. *LANCET* 360:878 (2002).
- Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, Brenner DE: Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis. *MELANOMA RES* 12:429-434 (2002).
- Woodward JKL, Elshaw SR, Murray AK, Nichols CE, Cross N, Laws D, Rennie IG, Sisley K: Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-alpha and TGF-&BETA. *INVEST OPHTHALMOL VISUAL SCI* 43:3144-3152 (2002).
- Yan L, Li DH, Yee JA: Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice. *CLIN EXP METASTAS* 19:535-540 (2002).
- Yarbro JW, Mastrangelo MJ: Melanoma I - American and European perspectives on diagnosis and treatment - Preface. *SEMIN ONCOL* 29:305 (2002).
- Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D, Hoo WS, Carlo DJ: Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. *GENE THERAPY* 9:1302-1311 (2002).
- Yokoyama S, Yamaue H: Prediction of distant metastasis by using reverse transcriptase-polymerase chain reaction for epithelial and variant CD44 mRNA in the peripheral blood of patients with colorectal cancer. *ARCH SURG* 137:1069-1073 (2002).
- Zhang LX, Akbulut H, Tang YC, Peng XY, Pizzorno G, Sapi E, Manegold S, Deisseroth A: Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. *MOL THER* 6:386-393 (2002).

### **MSH, POMC, GROWTH FACTORS & RECEPTORS**

- Argyropoulos G, Rankinen T, Neufeld DR, Rice T, Province MA, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C: A polymorphism in the human agouti-related protein is associated with late-onset obesity. *J CLIN ENDOCRINOL METAB* 87:4198-4202 (2002).
- Audinot V, Lahaye C, Suply T, Rovere-Jovene C, Rodriguez M, Nicolas JP, Beauverger P, Cardinaud B, Galizzi JP, Fauchere JL, Nahon JL, Boutin JA: SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor. *BIOCHEM BIOPHYS RES COMMUN* 295:841-848 (2002).
- Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricala C, Amantea A, Noonan DM, Albin A, Natali PG, Lombardi D, Paggi MG: The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. *ONCOGENE* 21:6684-6688 (2002).
- Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg DJ, Seeley RJ, Woods SC: The catabolic action of insulin in the brain is mediated by melanocortins. *J NEUROSCI* 22:9048-9052 (2002).
- Bhoomik A, Huang TG, Ivanov V, Gangi L, Qiao RF, Woo SLC, Chen SH, Ronai Z: An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. *J CLIN INVEST* 110:643-650 (2002).
- Bondebjerg J, Xiang ZM, Bauzo RM, Haskell-Luevano C, Meldal M: A solid-phase approach to mouse melanocortin receptor agonists derived from a novel thioether cyclized peptidomimetic scaffold. *J AM CHEM SOC* 124:11046-11055 (2002).
- Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C:

- Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist (vol 8, pg 825, 2002). *NATURE MED* 8:NIL (2002).
- Bradley RL, Mansfield JPR, Maratos-Flier E, Cheatham B: Melanin-concentrating hormone activates signaling pathways in 3T3-L1 adipocytes. *AMER J PHYSIOL ENDOCRINOL MET* 283:E584-E592 (2002).
- Butler AA, Cone RD: The melanocortin receptors: Lessons from knockout models. *NEUROPEPTIDES* 36:77-84 (2002).
- Casalino-Matsuda SM, Durando PE, Celis ME: Effects of alpha-MSH on progesterone and nitric oxide release by cultured ovarian granulosa cells in experimental rat autoimmune oophoritis. *J PHYSIOL BIOCHEM* 58:25-31 (2002).
- Challis BG, Pritchard LE, Creemers JWM, Delplanque J, Keogh JM, Luan J, Wareham NJ, Yeo GSH, Bhattacharyya S, Froguel P, White A, Farooqi IS, O'Rahilly S: A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. *HUM MOL GENET* 11:1997-2004 (2002).
- Cheung AWH, Danho W, Swistok J, Qi L, Kurylko G, Franco L, Yagaloff K, Chen L: Structure-activity relationship of linear peptide Bu-His- DPhe-Arg-Trp-Gly-NH<sub>2</sub> at the human melanocortin-1 and-4 receptors: Arginine substitution. *BIOORG.MEDICINAL CHEM LETTER*. 12:2407-2410 (2002).
- Della-Zuana O, Presse F, Ortola C, Duhault J, Nahon JL, Levens N: Acute and chronic administration of melanin-concentrating hormone enhances food intake and body weight in Wistar and Sprague-Dawley rats. *INT J OBESITY*. 26:1289-1295 (2002).
- Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, Servant M, Lin RT, Galipeau J, Hiscott J: In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. *CANCER RES* 62:5148-5152 (2002).
- Fried S, O'Neill K, Hawes BE: Cloning and characterization of rhesus monkey MCH-R1 and MCH-R2. *PEPTIDES* 23:1401-1408 (2002).
- Gao XB, van den Pol AN: Melanin-concentrating hormone depresses L-, N-, and P/Q- type voltage-dependent calcium channels in rat lateral hypothalamic neurons. *J PHYSIOL LONDON* 542:273-286 (2002).
- Getting SJ: Melanocortin peptides and their receptors: new targets for anti-inflammatory therapy. *TRENDS PHARMACOL SCI* 23:447-449 (2002).
- Hoogduijn MJ, Ancans J, Suzuki I, Estdale S, Thody AJ: Melanin-concentrating hormone and its receptor are expressed and functional in human skin. *BIOCHEM BIOPHYS RES COMMUN* 296:698-701 (2002).
- Kalat M, Kupcu Z, Schuller S, Zalusky D, Zehetner M, Paster W, Schweighoffer T: In vivo plasmid electroporation induces tumor antigen-specific CD8<sup>+</sup> T-Cell responses and delays tumor growth in a syngeneic mouse melanoma model. *CANCER RES* 62:5489-5494 (2002).
- Kim CS, Lee SH, Kim RY, Kim BJ, Li SZ, Lee IH, Lee EJ, Lim SK, Bae YS, Lee W, Baik JH: Identification of domains directing specificity of coupling to G-proteins for the melanocortin MC3 and MC4 receptors. *J BIOL CHEM* 277:31310-31317 (2002).
- Konstadoulakis MM, Messaris E, Zografos G, Ricaniadis N, Androulakis G, Karakousis C: Common prognostic factors for stage III melanoma patients and for stage I and II melanoma patients with recurrence to their regional lymph nodes. *MELANOMA RES* 12:357-364 (2002).
- Kretschmer L, Preusser KP, Neumann C: Locoregional cutaneous metastasis in patients with therapeutic lymph node dissection for malignant melanoma: risk factors and prognostic impact. *MELANOMA RES* 12:499-504 (2002).
- Langouche L, Pals K, Denef C: Structure-activity relationship and signal transduction of gamma-MSH peptides in GH3 cells: further evidence for a new melanocortin receptor. *PEPTIDES* 23:1077-1086 (2002).

- Lindblom J, Wikberg JES, Bergstrom L: Alcohol-preferring AA rats show a derangement in their central melanocortin signalling system. *PHARMACOL BIOCHEM BEHAV* 72:491-496 (2002).
- Liu X, Chen DW, Xie LP, Zhang RQ: Effect of honey bee venom on proliferation of K1735M2 mouse melanoma cells in-vitro and growth of murine B16 melanomas in-vivo. *J PHARM PHARMACOL* 54:1083-1089 (2002).
- Miao YB, Owen NK, Whitener D, Gallazzi F, Hoffman TJ, Quinn TP: In vivo evaluation of (188)re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. *INT J CANCER* 101:480-487 (2002).
- Milligan G: Strategies to identify ligands for orphan G-protein- coupled receptors. *BIOCHEM SOC TRANS* 30:789-793:789-793 (2002).
- Mills L, Tellez C, Huang SY, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M: Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. *CANCER RES* 62:5106-5114 (2002).
- Neef R, Kuske MA, Prols E, Johnson JP: Identification of the human PHLDA1/TDAG51 gene: Down- regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. *CANCER RES* 62:5920-5929 (2002).
- Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. *ONCOGENE* 21:7001-7010 (2002).
- Saito H, Yasumoto K, Takeda K, Takahashi K, Fukuzaki A, Orikasa S, Shibahara S: Melanocyte-specific microphthalmia-associated transcription factor isoform activates its own gene promoter through physical interaction with lymphoid- enhancing factor 1. *J BIOL CHEM* 277:28787-28794 (2002).
- Salazar-Onfray F, Lopez M, Lundqvist A, Aguirre A, Escobar A, Serrano A, Korenblit C, Petersson M, Chhajlani V, Larsson O, Kiessling R: Tissue distribution and differential expression of melanocortin I receptor, a malignant melanoma marker. *BRIT J CANCER* 87:414-422 (2002).
- Schrama D, Fuchs E, Brocker EB, Straten PT, Becker JC: Identical T-cell receptor transcripts in multiple melanoma metastases. *CANCER RES* 62:5664-5667 (2002).
- Smit MA, Shay TL, Beever JE, Notter DR, Cockett NE: Identification of an agouti-like locus in sheep. *ANIM GENET* 33:383-385 (2002).
- Takemoto CM, Yoon YH, Fisher DE: The identification and functional characterization of a novel mast cell isoform of the microphthalmia-associated transcription factor. *J BIOL CHEM* 277:30244-30252 (2002).
- Takenoya F, Funahashi H, Matsumoto H, Ohtaki T, Katoh S, Kageyama H, Suzuki R, Takeuchi M, Shioda S: Galanin-like peptide is co-localized with alpha-melanocyte stimulating hormone but not with neuropeptide Y in the rat brain. *NEUROSCI LETT* 331:119-122 (2002).
- Trikha M, Timar J, Zacharek A, Nemeth JA, Cai YL, Dome B, Somlai B, Raso E, Ladanyi A, Honn KV: Role for beta3 integrins in human melanoma growth and survival. *INT J CANCER* 101:156-167 (2002).
- Wang W, Cai MY, Xiong CY, Zhang JY, Trivedi D, Hrubby VJ: Design and synthesis of novel chi(2)-constrained phenylalanine, naphthylalanine, and tryptophan analogues and their use in biologically active melanotropin peptides. *TETRAHEDRON* 58:7365-7374 (2002).
- Widlund HR, Horstmann MA, Price ER, Cui JI, Lessnick SL, Wu M, He X, Fisher DE: beta-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. *J CELL BIOL* 158:1079-1087 (2002).
- Wolters FLC, de Vocht TF, Klis SFL, Hamers FPT, Smoorenburg GF: Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity. *HEAR RES* 172:110-117 (2002).
- Zhang JN, Nakayama J, Ohyama C, Suzuki M, Suzuki A, Fukuda M, Fukuda MN: Sialyl Lewis X-dependent lung colonization of B16 melanoma cells through a selectin-like endothelial receptor distinct from E- or P-selectin. *CANCER RES* 62:4194-4198 (2002).

Zuasti A: Melanization stimulating factor (MSF) and melanization inhibiting factor (MIF) in the integument of fish. *MICROSC RES TECHNIQUE* 58:488-495 (2002).

### DEVELOPMENTAL BIOLOGY

- Baxter LL, Pavan WJ: The oculocutaneous albinism type IV gene *Matp* is a new marker of pigment cell precursors during mouse embryonic development. *MECH DEVELOP* 116:209-212 (2002).
- Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A: Genome-wide association study and mouse model identify interaction between *RET* and *EDNRB* pathways in Hirschsprung disease. *NAT GENET* 32:237-244 (2002).
- Escribano J, Gandia-Herrero F, Caballero N, Pedreno MA: Subcellular localization and isoenzyme pattern of peroxidase and polyphenol oxidase in beet root (*Beta vulgaris* L.). *J AGR FOOD CHEM* 50:6123-6129 (2002).
- Firnberg N, Neubuser A: FGF signaling regulates expression of *Tbx2*, *Erm*, *Pea3*, and *Pax3* in the early nasal region. *DEVELOP BIOL* 247:237-250 (2002).
- Fox EA, Phillips RJ, Byerly MS, Baronowsky EA, Chi MM, Powley TL: Selective loss of vagal intramuscular mechanoreceptors in mice mutant for steel factor, the c-Kit receptor ligand. *ANAT EMBRYOL*. 205:325-342 (2002).
- Harris RG, White E, Phillips ES, Lillycrop KA: The expression of the developmentally regulated proto-oncogene *Pax-3* is modulated by N-Myc. *J BIOL CHEM* 277:34815-34825 (2002).
- Margenthaler JA, Johnson DY, Virgo KS, Fosko SW, Chan D, Goshima K, Handler BS, Johnson FE: Evaluation of patients with clinically suspected melanoma recurrence: Current practice patterns of plastic surgeons. *INT J ONCOL* 21:591-596 (2002).
- Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia A, Sanchez ML, Orfao A, Flores T, Sanchez-Garcia I: Zinc-finger transcription factor *Slug* contributes to the function of the stem cell factor c-kit signaling pathway. *BLOOD* 100:1274-1286 (2002).
- Peterson KA, King BL, Hagge-Greenberg A, Roix JJ, Bult CJ, O'Brien TP: Functional and comparative genomic analysis of the piebald deletion region of mouse chromosome 14. *GENOMICS* 80:172-184 (2002).
- Pingault V, Girard M, Bondurand N, Dorkins H, Van Maldergem L, Mowat D, Shimotake T, Verma I, Baumann C, Goossens M: *SOX10* mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism. *HUM GENET* 111:198-206 (2002).
- Puppo F, Griseri P, Fanelli M, Schena F, Romeo G, Pelicci P, Ceccherini I, Ravazzolo R, Patrone G: Cell-line specific chromatin acetylation at the *Sox10-Pax3* enhancer site modulates the *RET* proto-oncogene expression. *FEBS LETT* 523:123-127 (2002).
- Pusch CM, Sasiadek MM, Blin N: Hirschsprung, *RET-SOX* and beyond: The challenge of examining non-mendelian traits (Review). *INT J MOL MED* 10:367-370 (2002).
- Rajaraman S, Davis WS, Mahakali-Zama A, Evans HK, Russell LB, Bedell MA: An allelic series of mutations in the *Kit* ligand gene of mice. I. Identification of point mutations in seven ethylnitrosourea-induced *Kitl*(Steel) alleles. *GENETICS* 162:331-340 (2002).
- Rajaraman S, Davis WS, Mahakali-Zama A, Evans HK, Russell LB, Bedell MA: An allelic series of mutations in the *Kit* ligand gene of mice. II. Effects of ethylnitrosourea-induced *Kitl* point mutations on survival and peripheral blood cells of *Kitl*(Steel) mice. *GENETICS* 162:341-353 (2002).
- Rehberg S, Lischka P, Glaser G, Stamminger T, Wegner M, Rosorius O: *Sox10* is an active nucleocytoplasmic shuttle protein, and shuttling is crucial for *Sox10*-mediated transactivation. *MOL CELL BIOL* 22:5826-5834 (2002).
- Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM: Thin primary cutaneous melanomas - Associated detection patterns, lesion characteristics, and patient characteristics. *CANCER* 95:1562-1568 (2002).

von Boyen GBT, Krammer HJ, Suss A, Dembowski C, Ehrenreich H, Wedel T: Abnormalities of the enteric nervous system in heterozygous endothelin B receptor deficient (spotting lethal) rats resembling intestinal neuronal dysplasia. *GUT* 51:414-419 (2002).

### DIFFERENTIATION

- Aoki H, Moro O: Involvement of microphthalmia-associated transcription factor (MITF) in expression of human melanocortin-1 receptor (MC1R). *LIFE SCI* 71:2171-2179 (2002).
- Baurin N, Arnoult E, Scior T, Do QT, Bernard P: Preliminary screening of some tropical plants for anti-tyrosinase activity. *J ETHNOPHARMACOL* 82:155-158 (2002).
- Blechynen LM, Hilbert BJ, Swinburne JE, Binns MM, Laing NG: Four type I equine microsatellites associated with the MITF, KIT, ATP2A1 and GDAP1 genes. *ANIM GENET* 33:387-388 (2002).
- Curtis JT: A blond coat color variation in meadow vole (*Microtus pennsylvanicus*). *J HERED* 93:209-210 (2002).
- Dhillon WS, Small CJ, Stanley SA, Jethwa PH, Seal LJ, Murphy KG, Ghatgei MA, Bloom SR: Hypothalamic interactions between neuropeptide Y, agouti-related protein, cocaine- and amphetamine-regulated transcript and alpha-melanocyte-stimulating hormone in vitro in male rats. *J NEUROENDOCRINOL* 14:725-730 (2002).
- Erdmann PM, Lee RK, Bassett MJ, McClean PE: A molecular marker tightly linked to P, a gene required for flower and seedcoat color in common bean (*Phaseolus vulgaris* L.), contains the Ty3-gypsy retrotransposon Tpv3g. *GENOME* 45:728-736 (2002).
- Fukuda M: Synaptotagmin-like protein (Slp) homology domain 1 of Slac2-a/melanophilin is a critical determinant of GTP-dependent specific binding to Rab27A. *J BIOL CHEM* 277:40118-40124 (2002).
- Fukuda M, Kanno E, Saegusa C, Ogata Y, Kuroda TS: Slp4-a/granuphilin-a regulates dense-core vesicle exocytosis in PC12 cells. *J BIOL CHEM* 277:39673-39678 (2002).
- Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. *MOL GENET METAB* 76:234-242 (2002).
- Galy A, Neron B, Planque N, Saule S, Eychene A: Activated MAPK/ERK kinase (MEK-1) induces trans differentiation of pigmented epithelium into neural retina. *DEVELOP BIOL* 248:251-264 (2002).
- Gasowska B, Wojtasek H, Hurek J, Drag M, Nowak K, Kafarski P: Redox reaction between amino-(3,4-dihydroxyphenyl)methyl phosphonic acid and dopaquinone is responsible for the apparent inhibitory effect on tyrosinase. *EUR J BIOCHEM* 269:4098-4104 (2002).
- Halaban R, Cheng E, Hebert DN: Coexpression of wild-type tyrosinase enhances maturation of temperature-sensitive tyrosinase mutants. *J INVEST DERMATOL* 119:481-488 (2002).
- Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F: cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner. *ONCOGENE* 21:6101-6112 (2002).
- Henner J, Poncet PA, Guerin G, Hagger C, Stranzinger G, Rieder S: Genetic mapping of the (G)-locus, responsible for the coat color phenotype "progressive greying with age" in horses (*Equus caballus*). *MAMM GENOME* 13:535-537 (2002).
- Hirosaki K, Yamashita T, Wada I, Jin HY, Jimbow K: Tyrosinase and tyrosinase-related protein 1 require Rab7 for their intracellular transport. *J INVEST DERMATOL* 119:475-480 (2002).
- Housseau F, Lindsey KR, Oberholtzer SD, Gonzales MI, Boutin P, Moorthy AK, Shankara S, Roberts BL, Topalian SL: Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. *J IMMUNOL METHOD* 266:87-103 (2002).

- Kataoka TR, Morii E, Oboki K, Jippo T, Maeyama K, Kitamura Y: Dual abnormal effects of mutant MITF encoded by Mi(wh) allele on mouse mast cells: decreased but recognizable transactivation and inhibition of transactivation. *BIOCHEM BIOPHYS RES COMMUN* 297:111-115 (2002).
- Kim MS, Rossi M, Abbott CR, AlAhmed SH, Smith DM, Bloom SR: Sustained orexigenic effect of Agouti related protein may be not mediated by the melanocortin 4 receptor. *PEPTIDES* 23:1069-1076 (2002).
- Kitamura Y, Morii E, Jippo T, Ito A: Effect of MITF on mast cell differentiation. *MOL IMMUNOL* 38:1173-1176 (2002).
- Li CY, Wu TS: Constituents of the pollen of *Crocus sativus* L. and their tyrosinase inhibitory activity. *CHEM PHARM BULL TOKYO* 50:1305-1309 (2002).
- Locke MM, Penedo MCT, Bricker SJ, Millon LV, Murray JD: Linkage of the grey coat colour locus to microsatellites on horse chromosome 25. *ANIM GENET* 33:329-337 (2002).
- Mellado B, Vela MD, Colomer D, Gutierrez L, Castel T, Quinto L, Fontanillas M, Reguart N, Domingo-Domenech JM, Montagut C, Estape J, Gascon P: Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. *J CLIN ONCOL* 20:4032-4039 (2002).
- Moriyama K, Bonifacino JS: Pallidin is a component of a multi-protein complex involved in the biogenesis of lysosome-related organelles. *TRAFFIC* 3:666-677 (2002).
- Nechushtan H, Razin E: The function of MITF and associated proteins in mast cells. *MOL IMMUNOL* 38:1177-1180 (2002).
- Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT: Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. *CANCER RES* 62:4663-4670 (2002).
- Osella-Abate S, Quagliano P, Savoia P, Loporati C, Comessatti A, Bernengo MG: VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. *MELANOMA RES* 12:325-334 (2002).
- Rebbeck TR, Kanetsky PA, Walker AH, Holmes R, Halpern AC, Schuchter LM, Elder DE, Guerry D: P gene as an inherited biomarker of human eye color. *CANCER EPIDEM BIOMARKER PREV* 11:782-784 (2002).
- Rescigno A, Sollai F, Pisu B, Rinaldi A, Sanjust E: Tyrosinase inhibition: General and applied aspects. *J ENZYM INHIB.MED CHEM* 17:207-218 (2002).
- Schmutz SM, Berryere TG, Goldfinch AD: TYRP1 and MC1R genotypes and their effects on coat color in dogs. *MAMM GENOME* 13:380-387 (2002).
- Seetharam G, Saville BA: L-DOPA production from tyrosinase immobilized on zeolite. *ENZYME MICROB TECHNOL* 31:747-753 (2002).
- Starcevic M, Nazarian R, Dell'Angelica EC: The molecular machinery for the biogenesis of lysosome-related organelles: lessons from Hermansky-Pudlak syndrome. *SEMIN CELL DEV BIOL* 13:271-278 (2002).
- Swinburne JE, Hopkins A, Binns MM: Assignment of the horse grey coat colour gene to ECA25 using whole genome scanning. *ANIM GENET* 33:338-342 (2002).
- Szenajch J, Jasinski B, Kozak A, Kulik J, Chomicka M, Struzyna J, Nowecki Z, Rutkowski R, Ruka W, Kupsc W, Siedlecki J, Wiktor-Jedrzejczak W: Multiple RT-PCR tyrosinase testing reveals that melanoma cells circulate in the blood of melanoma patients at the frequency more than 10 times below the detection threshold. *MELANOMA RES* 12:399-401 (2002).
- Tepper AWJW, Bubacco L, Canters GW: Structural basis and mechanism of the inhibition of the type-3 copper protein tyrosinase from *Streptomyces antibioticus* by halide ions. *J BIOL CHEM* 277:30436-30444 (2002).
- Teus MA, Arranz-Marquez E, Lucea-Suescun P: Incidence of iris colour change in latanoprost treated eyes. *BRIT J OPHTHALMOL* 86:1085-1088 (2002).

- Toyofuku K, Valencia JC, Kushimoto T, Costin GE, Virador VM, Vieira WD, Ferrans VJ, Hearing VJ: The etiology of oculocutaneous albinism (OCA) type II: The pink protein controls the transport and processing of tyrosinase. (vol 15, pg 217, 2002). *PIGM CELL RES* 15:400 (2002).
- Voisey J, Imbeault P, Hutley L, Prins JB, van Daal A: Body mass index-related human adipocyte agouti expression is sex-specific but not depot-specific. *OBES.RES* 10:447-452 (2002).

#### MISCELLANEOUS

- de Gruijl FR: Photocarcinogenesis: UVA vs. UVB radiation. *SKIN PHARMACOL APPL SKIN PHYS* 15:316-320 (2002).
- Gollnick HPM, Siebenwirth C: beta-carotene plasma levels and content in oral mucosal epithelium is skin type associated. *SKIN PHARMACOL APPL SKIN PHYS* 15:360-366 (2002).
- Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A, Biesalski HK, Gollnick H: Photoprotection of UV-irradiated human skin: An antioxidative combination of vitamins E and C, carotenoids, selenium and proanthocyanidins. *SKIN PHARMACOL APPL SKIN PHYS* 15:307-315 (2002).
- Kuluncsics Z, Kerekgyarto T, Grof P, Horkay I, Ronto G: Biological UV dosimeters in quality control of tanning tubes. *PHOTOCHEM PHOTOBIOLOG* 76:391-396 (2002).
- Piccolo D, Ferrari A, Peris K, Daidone R, Ruggeri B, Chimenti S: Dermoscopic diagnosis by a trained clinician vs. a clinician with minimal dermoscopy training vs. computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. *BRIT J DERMATOL* 147:481-486 (2002).
- Rubegni P, Cevenini G, Burrioni M, Perotti R, Dell'Eva G, Sbano P, Miracco C, Luzi P, Tosi P, Barbini P, Andreassi L: Automated diagnosis of pigmented skin lesions. *INT J CANCER* 101:576-580 (2002).
- Rubegni P, Burrioni M, Cevenini G, Perotti R, Dell'Eva G, Barbini P, Fimiani M, Andreassi L: Digital dermoscopy analysis and artificial neural network for the differentiation of clinically atypical pigmented skin lesions: A retrospective study. *J INVEST DERMATOL* 119:471-474 (2002).
- Walton RG: Usefulness of dermoscopy in treating pigmented tumors. *ARCH DERMATOL* 138:1379-1380 (2002).
- Weismann K, Lorentzen HF, Larsen FG: Diagnostic Pearl: Bright field globe magnifier diascopy for large pigmented skin lesions: A practical approach to epiluminescence microscopy. *J AMER ACAD DERMATOL* 47:304-306 (2002).